European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision
Objective To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diag...
Uložené v:
| Vydané v: | European journal of neurology Ročník 28; číslo 11; s. 3556 - 3583 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
John Wiley & Sons, Inc
01.11.2021
|
| Predmet: | |
| ISSN: | 1351-5101, 1468-1331, 1468-1331 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Objective
To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Methods
Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis and treatment to guide the literature search. Data were extracted and summarized in GRADE summary of findings (for treatment PICOs) or evidence tables (for diagnostic PICOs).
Results
Statements were prepared according to the GRADE Evidence‐to‐Decision frameworks. Typical CIDP and CIDP variants were distinguished. The previous term “atypical CIDP” was replaced by “CIDP variants” because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP). The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP. The principal treatment recommendations were: (a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants; (b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective; (c) IVIg should be considered as first‐line treatment in motor CIDP (Good Practice Point); (d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended; (e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point); and (f) if pain is present, consider drugs against neuropathic pain and multidisciplinary management (Good Practice Point). |
|---|---|
| AbstractList | Objective
To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Methods
Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis and treatment to guide the literature search. Data were extracted and summarized in GRADE summary of findings (for treatment PICOs) or evidence tables (for diagnostic PICOs).
Results
Statements were prepared according to the GRADE Evidence‐to‐Decision frameworks. Typical CIDP and CIDP variants were distinguished. The previous term “atypical CIDP” was replaced by “CIDP variants” because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP). The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP. The principal treatment recommendations were: (a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants; (b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective; (c) IVIg should be considered as first‐line treatment in motor CIDP (Good Practice Point); (d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended; (e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point); and (f) if pain is present, consider drugs against neuropathic pain and multidisciplinary management (Good Practice Point). ObjectiveTo revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).MethodsSeventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis and treatment to guide the literature search. Data were extracted and summarized in GRADE summary of findings (for treatment PICOs) or evidence tables (for diagnostic PICOs).ResultsStatements were prepared according to the GRADE Evidence‐to‐Decision frameworks. Typical CIDP and CIDP variants were distinguished. The previous term “atypical CIDP” was replaced by “CIDP variants” because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP). The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP. The principal treatment recommendations were: (a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants; (b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective; (c) IVIg should be considered as first‐line treatment in motor CIDP (Good Practice Point); (d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended; (e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point); and (f) if pain is present, consider drugs against neuropathic pain and multidisciplinary management (Good Practice Point). To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).OBJECTIVETo revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis and treatment to guide the literature search. Data were extracted and summarized in GRADE summary of findings (for treatment PICOs) or evidence tables (for diagnostic PICOs).METHODSSeventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis and treatment to guide the literature search. Data were extracted and summarized in GRADE summary of findings (for treatment PICOs) or evidence tables (for diagnostic PICOs).Statements were prepared according to the GRADE Evidence-to-Decision frameworks. Typical CIDP and CIDP variants were distinguished. The previous term "atypical CIDP" was replaced by "CIDP variants" because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP). The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP. The principal treatment recommendations were: (a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants; (b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective; (c) IVIg should be considered as first-line treatment in motor CIDP (Good Practice Point); (d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended; (e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point); and (f) if pain is present, consider drugs against neuropathic pain and multidisciplinary management (Good Practice Point).RESULTSStatements were prepared according to the GRADE Evidence-to-Decision frameworks. Typical CIDP and CIDP variants were distinguished. The previous term "atypical CIDP" was replaced by "CIDP variants" because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP). The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP. The principal treatment recommendations were: (a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants; (b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective; (c) IVIg should be considered as first-line treatment in motor CIDP (Good Practice Point); (d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended; (e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point); and (f) if pain is present, consider drugs against neuropathic pain and multidisciplinary management (Good Practice Point). To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis and treatment to guide the literature search. Data were extracted and summarized in GRADE summary of findings (for treatment PICOs) or evidence tables (for diagnostic PICOs). Statements were prepared according to the GRADE Evidence-to-Decision frameworks. Typical CIDP and CIDP variants were distinguished. The previous term "atypical CIDP" was replaced by "CIDP variants" because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP). The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP. The principal treatment recommendations were: (a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants; (b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective; (c) IVIg should be considered as first-line treatment in motor CIDP (Good Practice Point); (d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended; (e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point); and (f) if pain is present, consider drugs against neuropathic pain and multidisciplinary management (Good Practice Point). |
| Author | Attarian, Shahram Eftimov, Filip Doorn, Pieter A. Allen, Jeffrey A. Vankrunkelsven, Patrik Lewis, Richard A. Topaloglu, Haluk A. Cornblath, David R. Lunn, Michael P. Goedee, H. Stephan Sommer, Claudia Avau, Bert Kuwabara, Satoshi Van den Bergh, Peter Y. K. Harbo, Thomas Rajabally, Yusuf A. Nobile‐Orazio, Eduardo Blomkwist‐Markens, Patricia H. Querol, Luis Hadden, Robert D. M. |
| Author_xml | – sequence: 1 givenname: Peter Y. K. orcidid: 0000-0003-1954-4617 surname: Van den Bergh fullname: Van den Bergh, Peter Y. K. email: peter.vandenbergh@uclouvain.be organization: University Hospital Saint‐Luc – sequence: 2 givenname: Pieter A. orcidid: 0000-0003-2584-3357 surname: Doorn fullname: Doorn, Pieter A. organization: University Medical Center – sequence: 3 givenname: Robert D. M. orcidid: 0000-0002-9702-0256 surname: Hadden fullname: Hadden, Robert D. M. organization: King's College Hospital – sequence: 4 givenname: Bert orcidid: 0000-0002-9160-084X surname: Avau fullname: Avau, Bert organization: Cochrane Belgium, CEBAM, Leuven, Belgium and CEBaP, Belgian Red Cross – sequence: 5 givenname: Patrik orcidid: 0000-0003-1047-9732 surname: Vankrunkelsven fullname: Vankrunkelsven, Patrik organization: Cochrane Belgium, CEBAM – sequence: 6 givenname: Jeffrey A. orcidid: 0000-0001-8753-2680 surname: Allen fullname: Allen, Jeffrey A. organization: University of Minnesota – sequence: 7 givenname: Shahram orcidid: 0000-0002-7211-4694 surname: Attarian fullname: Attarian, Shahram organization: Centre de Référence des Maladies Neuromusculaires et de la SLA, APHM, CHU Timone – sequence: 8 givenname: Patricia H. surname: Blomkwist‐Markens fullname: Blomkwist‐Markens, Patricia H. organization: Patient Representative GBS/CIDP Foundation International, International Office – sequence: 9 givenname: David R. orcidid: 0000-0003-2761-489X surname: Cornblath fullname: Cornblath, David R. organization: Johns Hopkins University School of Medicine – sequence: 10 givenname: Filip orcidid: 0000-0002-0146-0776 surname: Eftimov fullname: Eftimov, Filip organization: University of Amsterdam – sequence: 11 givenname: H. Stephan orcidid: 0000-0001-9591-1672 surname: Goedee fullname: Goedee, H. Stephan organization: University Medical Centre Utrecht – sequence: 12 givenname: Thomas orcidid: 0000-0003-2178-6076 surname: Harbo fullname: Harbo, Thomas organization: Århus University Hospital – sequence: 13 givenname: Satoshi orcidid: 0000-0002-4716-8578 surname: Kuwabara fullname: Kuwabara, Satoshi organization: Chiba University Hospital – sequence: 14 givenname: Richard A. orcidid: 0000-0002-1140-4575 surname: Lewis fullname: Lewis, Richard A. organization: Cedars‐Sinai Medical Center – sequence: 15 givenname: Michael P. orcidid: 0000-0003-3174-6027 surname: Lunn fullname: Lunn, Michael P. organization: National Hospital for Neurology and Neurosurgery – sequence: 16 givenname: Eduardo orcidid: 0000-0003-2624-8138 surname: Nobile‐Orazio fullname: Nobile‐Orazio, Eduardo organization: University of Milan – sequence: 17 givenname: Luis orcidid: 0000-0002-4289-8264 surname: Querol fullname: Querol, Luis organization: Hospital de la Santa Creu I Sant Pau – sequence: 18 givenname: Yusuf A. orcidid: 0000-0002-7170-8343 surname: Rajabally fullname: Rajabally, Yusuf A. organization: Queen Elizabeth Hospital Birmingham – sequence: 19 givenname: Claudia orcidid: 0000-0002-7064-5002 surname: Sommer fullname: Sommer, Claudia organization: University Hospital Würzburg – sequence: 20 givenname: Haluk A. orcidid: 0000-0002-3545-3830 surname: Topaloglu fullname: Topaloglu, Haluk A. organization: Yeditepe University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34327760$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctu1TAQhiNURC-w4AWQJTawSI8vuTjsquoUkKqCaFlHE2dyjg-OHeykKDsegofiOXgSnJ7CohJ4Y2v0_f_M-D9ODqyzmCTPGT1l8azQ4inLqrx6lByxrJApE4IdxLfIWZozyg6T4xB2lFJecvokORSZ4GVZ0KPk53rybkCw5ExBi_1MXEeuMBaN28yrj-j1sEUPJhb9LZJrpzSOM9lMukWjLRJnSathY13QgYBtyegRxh7tuFiprXdWK6JtZ6DvYXR-JkufRQyjthsyODN7aLWaTFxrGQfG7fyGfMLB-TsTIDuno98NhC_kwnmFv77_uEblYjePtzpoZ58mjzswAZ_d3yfJ54v1zfm79PLD2_fnZ5epElJWqWgKQNV2omVKNh2KTNKygE42JW1oXjLZtG1BIRelhA5kxxuegcilwKyitBInyau97-Dd1wnDWPc6KDQGLLop1DzPS85lRkVEXz5Ad27yNk4XKclFVgi-UC_uqanpsa0Hr3vwc_0nowi83gPKuxA8dn8RRusl_zrmX9_lH9nVA1bpMX6zs6MHbf6n-KYNzv-2rtdX673iN_90xuw |
| CitedBy_id | crossref_primary_10_3389_fneur_2024_1515161 crossref_primary_10_1136_jnnp_2021_328489 crossref_primary_10_1016_j_rmcr_2025_102295 crossref_primary_10_1212_WNL_0000000000209848 crossref_primary_10_3390_app15116137 crossref_primary_10_1007_s00415_025_13218_6 crossref_primary_10_1111_ene_16469 crossref_primary_10_1186_s12883_025_04312_3 crossref_primary_10_1111_ene_15496 crossref_primary_10_3390_ijms24119180 crossref_primary_10_1016_S1474_4422_24_00362_4 crossref_primary_10_1080_01616412_2025_2509154 crossref_primary_10_1007_s00415_024_12597_6 crossref_primary_10_1016_j_clinph_2023_12_005 crossref_primary_10_1016_j_intimp_2024_112083 crossref_primary_10_1212_WNL_0000000000209725 crossref_primary_10_1097_WCO_0000000000001399 crossref_primary_10_1111_jns_12605 crossref_primary_10_1016_j_jneuroim_2023_578238 crossref_primary_10_1016_S1474_4422_24_00309_0 crossref_primary_10_1007_s00115_024_01776_5 crossref_primary_10_1016_j_humimm_2024_111224 crossref_primary_10_1111_ene_70313 crossref_primary_10_1515_med_2025_1172 crossref_primary_10_1111_ene_70310 crossref_primary_10_1007_s00415_024_12548_1 crossref_primary_10_1007_s00415_024_12317_0 crossref_primary_10_1080_0886022X_2023_2209659 crossref_primary_10_1002_mus_28328 crossref_primary_10_1016_j_clineuro_2023_108017 crossref_primary_10_1093_brain_awae400 crossref_primary_10_1038_s41467_025_62964_8 crossref_primary_10_1080_01616412_2025_2530688 crossref_primary_10_1016_j_jns_2025_123654 crossref_primary_10_1007_s13760_023_02463_z crossref_primary_10_3389_fneur_2024_1495205 crossref_primary_10_1002_14651858_CD001797_pub4 crossref_primary_10_1007_s10072_023_06711_1 crossref_primary_10_3233_JND_240021 crossref_primary_10_1111_ene_15156 crossref_primary_10_1016_j_jad_2025_120204 crossref_primary_10_3389_fimmu_2022_1028282 crossref_primary_10_1002_mus_27820 crossref_primary_10_1002_mus_28239 crossref_primary_10_1002_ped4_70008 crossref_primary_10_1136_jnnp_2022_329633 crossref_primary_10_1186_s42466_024_00354_z crossref_primary_10_1002_mus_28478 crossref_primary_10_1007_s00115_022_01377_0 crossref_primary_10_1111_1744_9987_14223 crossref_primary_10_1055_a_2234_0105 crossref_primary_10_3390_neurolint15010027 crossref_primary_10_1007_s00415_024_12443_9 crossref_primary_10_4103_nsn_nsn_185_23 crossref_primary_10_1111_jns_70047 crossref_primary_10_1002_acn3_70036 crossref_primary_10_1080_14737175_2022_2147827 crossref_primary_10_3389_fneur_2021_809359 crossref_primary_10_1111_jns_70054 crossref_primary_10_1212_NXI_0000000000200295 crossref_primary_10_3389_fneur_2023_1126444 crossref_primary_10_1111_cen3_12788 crossref_primary_10_1002_mus_27498 crossref_primary_10_1016_j_clineuro_2025_108719 crossref_primary_10_1016_j_jns_2021_118055 crossref_primary_10_1136_jnnp_2022_329937 crossref_primary_10_3390_jcm12093281 crossref_primary_10_1016_j_jaut_2024_103305 crossref_primary_10_1111_ene_15693 crossref_primary_10_1159_000536167 crossref_primary_10_1111_jns_70017 crossref_primary_10_3389_fimmu_2025_1575464 crossref_primary_10_1080_13506129_2024_2409760 crossref_primary_10_1016_j_dscb_2025_100281 crossref_primary_10_3390_diagnostics15121484 crossref_primary_10_1177_22143602241304993 crossref_primary_10_1134_S1819712423040153 crossref_primary_10_17116_pain20252302145 crossref_primary_10_1002_mus_27726 crossref_primary_10_1111_jon_13162 crossref_primary_10_1002_mus_27722 crossref_primary_10_1002_mus_28014 crossref_primary_10_1186_s13023_025_03589_4 crossref_primary_10_3389_fneur_2023_1305497 crossref_primary_10_1007_s13760_022_01989_y crossref_primary_10_1155_2024_8584482 crossref_primary_10_3233_JAD_230419 crossref_primary_10_1111_ene_15225 crossref_primary_10_1002_acn3_51550 crossref_primary_10_1016_j_biopha_2023_114974 crossref_primary_10_1007_s00415_023_11625_1 crossref_primary_10_1136_jnnp_2023_332398 crossref_primary_10_1136_jnnp_2024_334678 crossref_primary_10_1055_s_0044_1791579 crossref_primary_10_1097_WCO_0000000000001183 crossref_primary_10_12968_hmed_2024_0544 crossref_primary_10_1038_s10038_021_01005_w crossref_primary_10_1002_mus_27713 crossref_primary_10_1002_mus_28249 crossref_primary_10_1111_jns_12638 crossref_primary_10_1136_bmjno_2024_000651 crossref_primary_10_1212_WNL_0000000000209777 crossref_primary_10_3390_medicina59061003 crossref_primary_10_4103_nsn_nsn_117_24 crossref_primary_10_1136_pn_2022_003655 crossref_primary_10_3390_brainsci13010010 crossref_primary_10_7759_cureus_44361 crossref_primary_10_1007_s40264_023_01326_z crossref_primary_10_3389_fped_2025_1610035 crossref_primary_10_3389_fimmu_2022_939062 crossref_primary_10_1002_mus_28391 crossref_primary_10_1055_s_0045_1809884 crossref_primary_10_1002_jca_22043 crossref_primary_10_1111_ene_16202 crossref_primary_10_1111_ene_16444 crossref_primary_10_1136_jnnp_2025_336458 crossref_primary_10_1177_11795735221084837 crossref_primary_10_1212_NXI_0000000000001160 crossref_primary_10_3390_diagnostics14131373 crossref_primary_10_3390_ijms24087288 crossref_primary_10_1136_jnnp_2023_332843 crossref_primary_10_1111_ene_16571 crossref_primary_10_3389_fimmu_2023_1189734 crossref_primary_10_3389_fimmu_2024_1345953 crossref_primary_10_1007_s13760_024_02557_2 crossref_primary_10_3390_ijms232113621 crossref_primary_10_3390_vaccines9121502 crossref_primary_10_1016_j_jneuroim_2023_578220 crossref_primary_10_1016_j_jns_2022_120478 crossref_primary_10_1016_j_vascn_2022_107187 crossref_primary_10_1007_s12026_023_09406_z crossref_primary_10_1111_jns_70007 crossref_primary_10_3389_fimmu_2024_1409637 crossref_primary_10_3389_fimmu_2022_986018 crossref_primary_10_7759_cureus_76749 crossref_primary_10_1177_09612033251314610 crossref_primary_10_1212_WNL_0000000000209879 crossref_primary_10_1016_j_revmed_2023_12_008 crossref_primary_10_1093_bjro_tzaf003 crossref_primary_10_1186_s12883_025_04233_1 crossref_primary_10_1186_s12883_025_04294_2 crossref_primary_10_1111_jns_12574 crossref_primary_10_1016_j_pop_2023_12_002 crossref_primary_10_1016_j_jns_2025_123397 crossref_primary_10_1016_j_clinph_2025_2110990 crossref_primary_10_1111_jns_12570 crossref_primary_10_1111_ene_70269 crossref_primary_10_1111_jns_12572 crossref_primary_10_1093_jnen_nlac085 crossref_primary_10_1111_ene_16073 crossref_primary_10_1093_cei_uxad103 crossref_primary_10_1111_ene_70267 crossref_primary_10_1111_ene_70023 crossref_primary_10_1053_j_seminhematol_2025_04_006 crossref_primary_10_1136_jnnp_2023_331378 crossref_primary_10_1136_bmjopen_2023_083669 crossref_primary_10_1016_j_clinph_2025_2110749 crossref_primary_10_7759_cureus_29390 crossref_primary_10_1002_mus_27640 crossref_primary_10_1093_jscr_rjaf596 crossref_primary_10_1016_j_jneuroim_2024_578348 crossref_primary_10_1016_j_jlr_2025_100903 crossref_primary_10_3389_fneur_2022_862335 crossref_primary_10_1111_jns_12569 crossref_primary_10_1016_j_jneuroim_2024_578460 crossref_primary_10_1016_j_jpsychores_2024_111830 crossref_primary_10_1038_s41572_024_00580_4 crossref_primary_10_1186_s12883_025_04330_1 crossref_primary_10_1002_mus_70025 crossref_primary_10_3389_fimmu_2021_759187 crossref_primary_10_3390_life15071036 crossref_primary_10_1007_s10072_024_07790_4 crossref_primary_10_1080_1744666X_2021_2002147 crossref_primary_10_7759_cureus_51648 crossref_primary_10_1155_crnm_8840308 crossref_primary_10_1007_s00415_025_13179_w crossref_primary_10_1055_a_2444_4629 crossref_primary_10_1111_ncn3_70045 crossref_primary_10_3389_fimmu_2023_1121705 crossref_primary_10_7759_cureus_91425 crossref_primary_10_1016_j_clinph_2023_11_020 crossref_primary_10_1016_j_jns_2024_122903 crossref_primary_10_3390_neurolint16060121 crossref_primary_10_1016_j_neurol_2023_02_064 crossref_primary_10_1080_14737175_2022_2169134 crossref_primary_10_1007_s10072_022_06215_4 crossref_primary_10_2147_TCRM_S360249 crossref_primary_10_1111_jns_12676 crossref_primary_10_1111_ene_16406 crossref_primary_10_1111_ncn3_12604 crossref_primary_10_1111_jns_12679 crossref_primary_10_1002_acn3_70205 crossref_primary_10_3389_fimmu_2025_1533167 crossref_primary_10_1212_WNL_0000000000213495 crossref_primary_10_1007_s40272_024_00646_6 crossref_primary_10_1016_j_ncl_2025_05_015 crossref_primary_10_1111_cen3_12816 crossref_primary_10_1212_NXI_0000000000200440 crossref_primary_10_1111_ene_16091 crossref_primary_10_3390_ijms23010179 crossref_primary_10_3390_jcm11154484 crossref_primary_10_1007_s00415_024_12860_w crossref_primary_10_1002_mus_27542 crossref_primary_10_1007_s10072_025_08278_5 crossref_primary_10_1002_ana_27203 crossref_primary_10_1002_mus_28199 crossref_primary_10_1007_s00415_023_11759_2 crossref_primary_10_1016_j_jneuroim_2024_578326 crossref_primary_10_1097_WCO_0000000000001407 crossref_primary_10_1007_s10072_023_07297_4 crossref_primary_10_1111_ncn3_12710 crossref_primary_10_1016_j_jns_2022_120279 crossref_primary_10_1111_jns_12545 crossref_primary_10_3390_jcm13102787 crossref_primary_10_1016_j_ejpn_2024_09_005 crossref_primary_10_1177_17562864221150540 crossref_primary_10_1097_j_pain_0000000000003300 crossref_primary_10_7759_cureus_46643 crossref_primary_10_1016_j_neurol_2022_06_008 crossref_primary_10_7759_cureus_67686 crossref_primary_10_1002_mus_27655 crossref_primary_10_1371_journal_pone_0315760 crossref_primary_10_1186_s12882_024_03830_5 crossref_primary_10_1002_mus_28068 crossref_primary_10_1016_j_neurol_2022_06_004 crossref_primary_10_1002_mus_28098 crossref_primary_10_1007_s00415_023_11908_7 crossref_primary_10_1016_j_jneuroim_2025_578556 crossref_primary_10_1002_brb3_3256 crossref_primary_10_1097_CND_0000000000000495 crossref_primary_10_1007_s00415_025_13175_0 crossref_primary_10_1111_ene_15296 crossref_primary_10_1016_j_pathol_2025_06_009 crossref_primary_10_3390_jcm13195721 crossref_primary_10_1007_s13311_021_01117_3 crossref_primary_10_1016_j_cca_2025_120479 crossref_primary_10_1002_mus_28419 crossref_primary_10_3389_fneur_2024_1358881 crossref_primary_10_3390_medicina59122160 crossref_primary_10_1016_j_ncl_2025_05_006 crossref_primary_10_1016_j_ncl_2025_05_007 crossref_primary_10_1016_j_neurol_2024_09_002 crossref_primary_10_61958_NCUF9652 crossref_primary_10_1016_j_jneuroim_2024_578381 crossref_primary_10_1111_jns_12481 crossref_primary_10_1111_ene_16399 crossref_primary_10_4103_aian_aian_756_24 crossref_primary_10_1111_ene_16285 crossref_primary_10_1007_s00415_024_12812_4 crossref_primary_10_1212_CPJ_0000000000001150 crossref_primary_10_7759_cureus_47475 crossref_primary_10_1177_11772719251349605 crossref_primary_10_1007_s00415_024_12456_4 crossref_primary_10_1016_j_autrev_2022_103032 crossref_primary_10_1186_s12883_023_03223_5 crossref_primary_10_1016_j_jns_2022_120500 crossref_primary_10_1111_ene_70209 crossref_primary_10_1097_CND_0000000000000473 crossref_primary_10_3390_ijms26073377 crossref_primary_10_1016_j_yexmp_2024_104942 crossref_primary_10_1111_jns_12594 crossref_primary_10_1007_s00415_024_12252_0 crossref_primary_10_1016_j_parkreldis_2023_105953 crossref_primary_10_1016_S1634_7072_22_47358_2 crossref_primary_10_1212_WNL_0000000000209900 crossref_primary_10_3389_fimmu_2022_890142 crossref_primary_10_1016_j_heliyon_2023_e20624 crossref_primary_10_1002_acn3_51978 crossref_primary_10_3389_fimmu_2024_1308068 crossref_primary_10_1016_j_msard_2022_103893 crossref_primary_10_1111_ene_15642 crossref_primary_10_2147_ITT_S388151 crossref_primary_10_1007_s00415_022_11283_9 crossref_primary_10_1002_brb3_70717 crossref_primary_10_1111_ene_70335 crossref_primary_10_1111_bpa_13184 crossref_primary_10_1213_XAA_0000000000001956 crossref_primary_10_1038_s41582_025_01133_3 crossref_primary_10_1080_14737175_2022_2036125 crossref_primary_10_5692_clinicalneurol_cn_002139 crossref_primary_10_3233_JND_221615 |
| Cites_doi | 10.1111/j.1085-9489.2005.0010206.x 10.1016/S1474-4422(08)70299-0 10.1016/S0035-3787(05)85198-7 10.1212/WNL.0000000000001833 10.1016/S0960-8966(00)00119-X 10.1002/(SICI)1096-9136(199705)14:5<353::AID-DIA343>3.0.CO;2-E 10.1136/jnnp.2007.116368 10.1111/j.1529-8027.2010.00245.x 10.1007/s40122-019-0128-y 10.1016/j.jns.2015.11.048 10.1002/ana.410360607 10.1212/WNL.51.6.1735 10.1111/j.1529-8027.2010.00290.x 10.1136/jnnp.2005.074781 10.1503/cmaj.090449 10.1007/s00415-017-8462-7 10.1002/jca.21546 10.1186/1471-2377-14-72 10.1136/jnnp.2009.188912 10.1159/000381767 10.1002/mus.26821 10.1186/s12883-017-0906-2 10.1097/WCO.0000000000000607 10.1212/01.WNL.0000142507.12763.58 10.1007/s00415-005-0848-2 10.1212/WNL.0000000000010369 10.4103/0028-3886.68673 10.1097/CND.0b013e31822484fb 10.1016/S0022-510X(03)00010-8 10.1136/jnnp.2009.194324 10.1212/WNL.0000000000008978 10.1212/WNL.56.1.94 10.1002/mus.20140 10.1016/j.jclinepi.2016.07.006 10.1212/WNL.35.8.1173 10.1056/NEJM198602203140801 10.1111/j.1468-1331.2012.03851.x 10.1002/(SICI)1097-4598(200002)23:2<283::AID-MUS23>3.0.CO;2-Q 10.1136/jnnp.60.2.185 10.1111/j.1468-1331.2009.02930.x 10.1136/jnnp.61.1.36 10.1007/s00415-014-7357-0 10.1111/jns.12169 10.1212/WNL.0000000000003483 10.1007/s00415-018-9157-4 10.1016/S1474-4422(14)70251-0 10.1016/j.clinph.2014.11.027 10.1002/mus.25271 10.1016/j.clinph.2019.12.404 10.1136/jnnp.64.1.84 10.1136/jnnp.72.5.596 10.1002/mus.26028 10.1212/01.wnl.0000188879.19900.b7 10.1016/j.transci.2005.07.010 10.1016/S1474-4422(12)70093-5 10.1016/j.clinph.2007.06.014 10.1002/(SICI)1097-4598(199905)22:5<560::AID-MUS2>3.0.CO;2-Q 10.1136/jnnp.57.7.778 10.1002/mus.880180411 10.1111/ene.13380 10.1002/mus.26747 10.1016/j.transci.2016.01.003 10.1007/s004150170093 10.1016/S1474-4422(07)70329-0 10.1001/archneurol.2010.105 10.1002/mus.20024 10.1136/jnnp-2020-324012 10.1111/jns.12318 10.1016/S1474-4422(10)70021-1 10.1016/S1474-4422(17)30378-2 10.1212/WNL.54.1.26 10.1212/WNL.0b013e31824e8f84 10.1002/ana.23794 10.1111/jns.12242 10.1159/000095139 10.1016/S0022-510X(01)00478-6 10.1212/WNL.43.11.2202 10.1016/j.jneuroim.2020.577288 10.1136/jnnp.2003.035428 10.1111/jns.12147 10.1097/01.sap.0000221963.66229.b6 10.1212/WNL.32.9.958 10.1111/jns.12158 10.1111/jns.12380 10.4103/0972-2327.160065 10.1097/j.pain.0000000000000539 10.1002/mus.26826 10.1136/jnnp-2018-319077 10.1136/jnnp-2013-307515 10.1136/jnnp-2018-318170 10.1016/0022-510X(76)90213-6 10.1111/jns.12378 10.1212/WNL.52.3.498 10.1212/NXI.0000000000000590 10.1093/brain/119.4.1055 10.1212/WNL.48.4.874 10.1002/ana.24314 10.1046/j.1468-1331.2002.00478.x 10.1212/WNL.0000000000002418 10.1007/978-1-4614-6567-6_29 10.1111/ene.12818 10.1212/WNL.49.1.253 10.1111/ene.12080 10.1001/archneur.57.12.1745 10.1002/mus.21171 10.1212/WNL.0b013e3181e07d14 10.1136/jnnp.55.8.677 10.1136/practneurol-2014-000831 10.1136/jnnp-2013-306014 10.1111/j.1529-8027.2009.00221.x 10.1016/S0041-1345(98)01389-X 10.1212/WNL.50.4.1179 10.1007/s00415-013-6938-7 10.1093/brain/awx124 10.1212/WNL.0b013e318208824b 10.1136/jnnp.2009.179358 10.1007/s10072-017-3133-0 10.1111/j.1085-9489.2005.10302.x 10.1007/s004150050531 10.1136/bmjopen-2013-003443 10.1111/j.1468-1331.2010.02999.x 10.1002/mus.10348 10.1111/j.1529-8027.2010.00251.x 10.1016/j.jclinepi.2013.02.003 10.1212/WNL.50.2.480 10.1111/j.1468-1331.2011.03495.x 10.1007/s00415-009-5437-3 10.1002/(SICI)1097-4598(199712)20:12<1569::AID-MUS12>3.0.CO;2-W 10.1111/ene.14053 10.1002/mus.24424 10.1136/jnnp.2004.056515 10.1002/(SICI)1097-4598(199804)21:4<454::AID-MUS3>3.0.CO;2-8 10.1016/j.jneuroim.2007.07.005 10.1212/WNL.47.1.98 10.1111/jns.12408 10.1111/j.1600-0404.1990.tb01011.x 10.1212/WNL.53.1.57 10.1007/s00415-016-8305-y 10.1016/j.jns.2004.05.014 10.1016/j.jns.2014.04.033 10.1093/brain/aww189 10.1002/brb3.1115 10.1002/(SICI)1097-4598(200001)23:1<73::AID-MUS9>3.0.CO;2-5 10.1002/mus.25997 10.1038/nrneurol.2017.84 10.1002/mus.20313 10.1007/s00415-020-10232-8 10.1111/jns5.12017 10.3389/fimmu.2018.01029 10.1097/SAP.0b013e31817e9c8d 10.1002/ana.22334 10.1002/mus.26488 10.1136/jnnp.2009.177576 10.1111/j.1529-8027.2010.00276.x 10.1016/S0022-510X(00)00493-7 10.1111/jns.12325 10.1007/s00415-017-8599-4 10.1002/acn3.539 10.1002/mus.24088 10.1016/j.nmd.2016.10.008 10.1002/mus.21480 10.1002/mus.26715 10.1212/WNL.0000000000000205 10.1038/s41598-019-42545-8 10.1212/01.wnl.0000167549.09664.b8 10.1111/j.1085-9489.2005.10306.x 10.1016/j.jns.2008.11.015 10.1016/S1474-4422(18)30202-3 10.1212/WNL.0000000000008697 10.1136/jnnp-2014-309916 10.1111/j.1468-1331.2010.03312.x 10.1212/01.wnl.0000223577.69111.2c 10.1212/WNL.0000000000006625 10.1111/j.1085-9489.2005.10104.x 10.1136/jnnp-2018-318714 10.1212/WNL.0000000000011703 10.1093/brain/awab014 10.1002/mus.21199 10.1212/WNL.54.4.943 10.1002/ana.410110205 10.1002/acn3.248 10.1111/j.1468-1331.2006.01278.x 10.1093/brain/122.7.1383 10.1002/mus.20438 10.1016/j.jclinepi.2016.01.032 10.1002/mus.24496 10.1002/mus.10361 10.1007/s004150050314 10.1212/WNL.54.3.615 10.1111/jns.12396 10.1136/jnnp.2010.206599 10.1212/WNL.50.1.84 10.1212/NXI.0000000000000639 10.1097/CND.0000000000000083 10.1093/brain/awv054 10.1002/mus.20664 10.1111/j.1468-1331.2009.02802.x 10.1007/s00415-013-7123-8 10.1212/01.WNL.0000134676.05850.C0 10.1136/jnnp-2014-309042 10.1002/mus.20022 10.1002/mus.21186 10.1136/jnnp-2013-306105 10.1002/mus.23821 10.1212/NXI.0000000000000149 10.1093/brain/119.3.765 10.1212/NXI.0000000000000603 10.1212/01.wnl.0000260972.07422.ea 10.1002/mus.880160304 10.1136/jnnp-2011-301706 10.1111/ene.13218 10.1212/WNL.0b013e3181d1a862 10.1212/WNL.58.12.1856 10.1136/bmj.i2089 |
| ContentType | Journal Article |
| Copyright | 2021 European Academy of Neurology and Peripheral Nerve Society 2021 European Academy of Neurology and Peripheral Nerve Society. Copyright © 2021 European Academy of Neurology |
| Copyright_xml | – notice: 2021 European Academy of Neurology and Peripheral Nerve Society – notice: 2021 European Academy of Neurology and Peripheral Nerve Society. – notice: Copyright © 2021 European Academy of Neurology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7U7 C1K K9. 7X8 |
| DOI | 10.1111/ene.14959 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-1331 |
| EndPage | 3583 |
| ExternalDocumentID | 34327760 10_1111_ene_14959 ENE14959 |
| Genre | shortArticle Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: GBS/CIDP Foundation International – fundername: GAIN Charity UK – fundername: Peripheral Nerve Society (PNS) – fundername: European Academy of Neurology (EAN) |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 169 1OB 1OC 24P 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAHHS AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCMX ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADPDF ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFGKR AFKRA AFPWT AFRAH AFWVQ AFZJQ AHMBA AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN ESX EX3 F00 F5P FEDTE FUBAC FYBCS FYUFA G-S G.N GODZA H.X HF~ HMCUK HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIG RIWAO RJQFR ROL RPM RX1 SAMSI SUPJJ TEORI UB1 UKHRP W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AGQPQ AGXDD AIDQK AIDYY AIQQE CITATION GROUPED_DOAJ O8X PHGZM WIN CGR CUY CVF ECM EIF NPM 7TK 7U7 C1K K9. 7X8 |
| ID | FETCH-LOGICAL-c3889-3b6aecdf3d1c8bfe348076af8b70b05718bdd60a5378afa8f2b24a3583e490093 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 303 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000679448800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1351-5101 1468-1331 |
| IngestDate | Thu Oct 02 06:08:31 EDT 2025 Sat Nov 29 14:33:20 EST 2025 Thu Apr 03 06:53:35 EDT 2025 Tue Nov 18 22:06:59 EST 2025 Sat Nov 29 05:12:51 EST 2025 Wed Jan 22 16:28:43 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | treatment GRADE diagnosis CIDP guideline |
| Language | English |
| License | 2021 European Academy of Neurology and Peripheral Nerve Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3889-3b6aecdf3d1c8bfe348076af8b70b05718bdd60a5378afa8f2b24a3583e490093 |
| Notes | This article is co‐published by the European Journal of Neurology and the Journal of the Peripheral Nervous System. See editorial by J.‐M. Vallat et al. on page 3545 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1140-4575 0000-0002-4716-8578 0000-0002-9702-0256 0000-0001-9591-1672 0000-0003-2624-8138 0000-0003-1954-4617 0000-0002-4289-8264 0000-0003-2761-489X 0000-0002-9160-084X 0000-0003-2584-3357 0000-0002-0146-0776 0000-0002-7064-5002 0000-0003-3174-6027 0000-0002-7170-8343 0000-0003-1047-9732 0000-0001-8753-2680 0000-0002-3545-3830 0000-0002-7211-4694 0000-0003-2178-6076 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14959 |
| PMID | 34327760 |
| PQID | 2582346323 |
| PQPubID | 1066358 |
| PageCount | 27 |
| ParticipantIDs | proquest_miscellaneous_2557228403 proquest_journals_2582346323 pubmed_primary_34327760 crossref_primary_10_1111_ene_14959 crossref_citationtrail_10_1111_ene_14959 wiley_primary_10_1111_ene_14959_ENE14959 |
| PublicationCentury | 2000 |
| PublicationDate | November 2021 2021-11-00 20211101 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: November 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | European journal of neurology |
| PublicationTitleAlternate | Eur J Neurol |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc |
| References | 2019; 90 2013; 3 2010; 15 2013; 66 2004; 29 2009; 80 2015; 73 2010; 17 2006; 33 2017; 88 1997; 48 2008; 38 2015; 77 2005; 65 1997; 49 2007; 190 1997; 2 2010; 182 2012; 13 1992; 55 2007; 78 2012; 11 1997; 8 2018; 9 2009; 14 2018; 8 2018; 5 2018; 4 2015; 138 2020; 95 2020; 94 2000; 10 2019; 24 2015; 86 2015; 85 1996; 61 2016; 157 1996; 60 2014; 14 2005; 76 1999; 53 1999; 52 2011; 69 2001; 56 2018; 31 2007; 68 2010; 9 2019; 8 2019; 9 2009; 62 2019; 6 2015; 126 2006; 56 2002; 9 2006; 57 2015; 51 1997; 20 2002; 72 2011; 82 1993; 43 1982; 32 2016; 10 1999; 22 2011; 76 2021; 144 2020; 268 1998; 64 2010; 41 2003; 210 1995; 8 2018; 17 2017; 55 2013; 73 2016; 21 2015; 2015 2020; 27 2005; 10 2003; 27 2020; 25 2017; 140 2014; 261 2017; 264 1996; 119 2004; 63 2002; 58 2001; 101 2001; 184 2017; 1 2010; 58 2005; 252 2001; 185 2006; 77 2020; 61 2013; 20 1982; 11 2016; 76 2009; 277 2008; 7 1999; 246 1999; 122 2018; 89 1976; 27 2011; 18 2007; 35 2010; 67 2020; 7 2013; 18 2019; 60 2019; 61 2006; 67 2020; 131 2000; 57 2017; 38 2000; 54 1997; 14 2017; 32 1943 2016; 86 2016; 353 2005; 31 1994; 36 1998; 50 2016; 80 1998; 51 2014; 50 2010; 74 2005; 33 2015; 2 2012; 83 2015; 14 2013; 48 2015; 17 1986; 314 2004; 224 2015; 18 2006; 13 2000; 23 2017; 27 2017; 22 2017; 24 2016; 54 2020; 345 2014; 85 2010; 81 2012; 78 2021; 96 2013; 260 1998; 21 2014; 82 1990; 81 2019; 266 2016; 360 2021; 92 2001; 248 2005; 161 2007; 118 1993; 16 2017; 17 2020 2015; 20 2010; 257 2015; 22 2017; 13 1994; 57 2009; 8 2016; 139 2014 2013 1996; 47 1998; 30 2014; 342 1985; 35 2018; 57 2009; 39 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_203_1 e_1_2_8_226_1 e_1_2_8_132_1 e_1_2_8_155_1 e_1_2_8_178_1 e_1_2_8_9_1 e_1_2_8_117_1 e_1_2_8_170_1 e_1_2_8_193_1 e_1_2_8_64_1 e_1_2_8_87_1 e_1_2_8_38_1 e_1_2_8_215_1 e_1_2_8_120_1 e_1_2_8_143_1 e_1_2_8_166_1 e_1_2_8_189_1 e_1_2_8_91_1 Jeanjean AP (e_1_2_8_46_1) 2001; 101 e_1_2_8_99_1 e_1_2_8_105_1 e_1_2_8_128_1 e_1_2_8_181_1 e_1_2_8_53_1 e_1_2_8_76_1 e_1_2_8_30_1 e_1_2_8_25_1 Schünemann HJ (e_1_2_8_6_1) 2013 e_1_2_8_48_1 e_1_2_8_204_1 e_1_2_8_2_1 e_1_2_8_133_1 e_1_2_8_110_1 e_1_2_8_171_1 e_1_2_8_86_1 e_1_2_8_118_1 e_1_2_8_194_1 e_1_2_8_63_1 Rajabally YA (e_1_2_8_15_1) 2019; 8 e_1_2_8_40_1 e_1_2_8_156_1 e_1_2_8_14_1 e_1_2_8_37_1 e_1_2_8_216_1 e_1_2_8_144_1 e_1_2_8_90_1 Kitakule MM (e_1_2_8_227_1) 1997; 8 e_1_2_8_121_1 e_1_2_8_98_1 e_1_2_8_182_1 e_1_2_8_75_1 e_1_2_8_129_1 e_1_2_8_52_1 e_1_2_8_167_1 e_1_2_8_28_1 e_1_2_8_220_1 Oh SJ (e_1_2_8_45_1) 1997; 2 e_1_2_8_205_1 e_1_2_8_81_1 e_1_2_8_111_1 e_1_2_8_7_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_66_1 e_1_2_8_89_1 e_1_2_8_119_1 e_1_2_8_172_1 e_1_2_8_195_1 e_1_2_8_134_1 e_1_2_8_157_1 e_1_2_8_17_1 e_1_2_8_217_1 e_1_2_8_70_1 e_1_2_8_122_1 e_1_2_8_160_1 e_1_2_8_32_1 e_1_2_8_55_1 e_1_2_8_78_1 e_1_2_8_107_1 e_1_2_8_183_1 e_1_2_8_145_1 e_1_2_8_168_1 e_1_2_8_93_1 e_1_2_8_221_1 e_1_2_8_27_1 e_1_2_8_206_1 e_1_2_8_80_1 e_1_2_8_150_1 e_1_2_8_8_1 e_1_2_8_42_1 e_1_2_8_88_1 e_1_2_8_65_1 e_1_2_8_112_1 e_1_2_8_158_1 e_1_2_8_196_1 e_1_2_8_135_1 e_1_2_8_39_1 e_1_2_8_210_1 Medical Research Council (e_1_2_8_100_1) 1943 e_1_2_8_16_1 e_1_2_8_218_1 e_1_2_8_92_1 e_1_2_8_161_1 e_1_2_8_31_1 e_1_2_8_77_1 e_1_2_8_54_1 e_1_2_8_108_1 e_1_2_8_184_1 e_1_2_8_123_1 e_1_2_8_169_1 e_1_2_8_146_1 e_1_2_8_68_1 e_1_2_8_222_1 e_1_2_8_207_1 Psimaras D (e_1_2_8_84_1) 2019; 24 e_1_2_8_5_1 e_1_2_8_151_1 e_1_2_8_22_1 e_1_2_8_113_1 e_1_2_8_136_1 e_1_2_8_159_1 e_1_2_8_174_1 e_1_2_8_197_1 e_1_2_8_60_1 e_1_2_8_83_1 e_1_2_8_19_1 e_1_2_8_109_1 e_1_2_8_57_1 e_1_2_8_211_1 e_1_2_8_95_1 e_1_2_8_219_1 e_1_2_8_162_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_101_1 e_1_2_8_124_1 e_1_2_8_147_1 e_1_2_8_185_1 e_1_2_8_72_1 e_1_2_8_29_1 e_1_2_8_200_1 e_1_2_8_223_1 e_1_2_8_152_1 e_1_2_8_208_1 e_1_2_8_21_1 e_1_2_8_67_1 e_1_2_8_44_1 e_1_2_8_137_1 e_1_2_8_175_1 e_1_2_8_82_1 e_1_2_8_114_1 e_1_2_8_198_1 e_1_2_8_18_1 e_1_2_8_79_1 e_1_2_8_212_1 e_1_2_8_94_1 e_1_2_8_163_1 e_1_2_8_140_1 e_1_2_8_10_1 e_1_2_8_56_1 e_1_2_8_33_1 e_1_2_8_102_1 e_1_2_8_148_1 e_1_2_8_186_1 e_1_2_8_71_1 e_1_2_8_125_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_224_1 e_1_2_8_201_1 e_1_2_8_3_1 e_1_2_8_130_1 e_1_2_8_153_1 e_1_2_8_209_1 e_1_2_8_138_1 e_1_2_8_62_1 Velasco R (e_1_2_8_85_1) 2019; 24 e_1_2_8_115_1 e_1_2_8_176_1 e_1_2_8_199_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_59_1 e_1_2_8_190_1 e_1_2_8_213_1 Oaklander AL (e_1_2_8_106_1) 2017; 1 e_1_2_8_141_1 e_1_2_8_164_1 e_1_2_8_97_1 e_1_2_8_149_1 Eftimov F (e_1_2_8_173_1) 2013 e_1_2_8_51_1 e_1_2_8_74_1 e_1_2_8_103_1 e_1_2_8_126_1 e_1_2_8_187_1 Lunn MP (e_1_2_8_41_1) 2016; 10 e_1_2_8_69_1 e_1_2_8_180_1 e_1_2_8_202_1 e_1_2_8_225_1 e_1_2_8_154_1 e_1_2_8_4_1 e_1_2_8_131_1 Mehndiratta MM (e_1_2_8_179_1) 2015; 2015 e_1_2_8_192_1 e_1_2_8_116_1 e_1_2_8_23_1 e_1_2_8_139_1 e_1_2_8_61_1 e_1_2_8_177_1 e_1_2_8_35_1 e_1_2_8_58_1 e_1_2_8_191_1 e_1_2_8_214_1 e_1_2_8_165_1 e_1_2_8_96_1 e_1_2_8_142_1 e_1_2_8_127_1 e_1_2_8_12_1 e_1_2_8_73_1 e_1_2_8_50_1 e_1_2_8_104_1 e_1_2_8_188_1 34152068 - Eur J Neurol. 2021 Nov;28(11):3545-3546 35032084 - Eur J Neurol. 2022 Jan 14 |
| References_xml | – volume: 17 start-page: 35 year: 2018 end-page: 46 article-title: Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double‐blind, placebo‐controlled, phase 3 trial publication-title: Lancet Neurol – volume: 25 start-page: 238 year: 2020 end-page: 246 article-title: Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy publication-title: J Peripher Nerv Syst – volume: 57 start-page: 778 year: 1994 end-page: 783 article-title: Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin publication-title: J Neurol Neurosurg Psychiatry – volume: 81 start-page: 634 year: 2010 end-page: 636 article-title: Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy publication-title: J Neurol Neurosurg Psychiatry – volume: 72 start-page: 596 year: 2002 end-page: 601 article-title: Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies publication-title: J Neurol Neurosurg Psychiatry – volume: 36 start-page: 838 year: 1994 end-page: 845 article-title: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Ann Neurol – volume: 9 start-page: 683 year: 2002 end-page: 685 article-title: Mycophenolate in treatment‐resistant inflammatory neuropathies publication-title: Eur J Neurol – volume: 13 start-page: 533 year: 2017 end-page: 547 article-title: Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications publication-title: Nat Rev Neurol – volume: 27 start-page: 290 year: 2017 end-page: 293 article-title: Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti‐neurofascin 155 antibodies publication-title: Neuromuscul Disord – volume: 15 start-page: 1 year: 2010 end-page: 9 article-title: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society—First Revision publication-title: J Peripher Nerv Syst – volume: 8 start-page: 158 year: 2009 end-page: 164 article-title: Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study publication-title: Lancet Neurol – volume: 64 start-page: 84 year: 1998 end-page: 89 article-title: Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy publication-title: J Neurol Neurosurg Psychiatry – volume: 10 start-page: 282 year: 2005 end-page: 292 article-title: Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases publication-title: J Peripher Nerv Syst – volume: 30 start-page: 4194 year: 1998 article-title: Positive effects of tacrolimus in a case of CIDP publication-title: Transplant Proc – volume: 8 start-page: 177 year: 2019 end-page: 185 article-title: Pain in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta‐analysis publication-title: Pain Ther – volume: 60 start-page: 185 year: 1996 end-page: 187 article-title: Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin‐A publication-title: J Neurol Neurosurg Psychiatry – volume: 35 start-page: 66 year: 2007 end-page: 69 article-title: Rituximab treatment in patients with IVIg‐dependent immune polyneuropathy: a prospective pilot trial publication-title: Muscle Nerve – volume: 50 start-page: 1179 year: 1998 end-page: 1182 article-title: Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy publication-title: Neurology – volume: 9 start-page: 1 year: 2018 end-page: 14 article-title: Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance publication-title: Front Immunol – volume: 268 start-page: 978 year: 2020 end-page: 988 article-title: Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies publication-title: J Neurol – volume: 29 start-page: 565 year: 2004 end-page: 574 article-title: Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Muscle Nerve – volume: 61 start-page: 779 year: 2020 end-page: 783 article-title: Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies publication-title: Muscle Nerve – volume: 10 start-page: 220 year: 2005 end-page: 228 article-title: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society publication-title: J Peripher Nerv Syst – volume: 8 start-page: 440 year: 1995 end-page: 444 article-title: Late motor involvement in cases presenting as “chronic sensory demyelinating polyneuropathy” publication-title: Muscle Nerve – volume: 63 start-page: 1662 year: 2004 end-page: 1669 article-title: Chronic immune sensory polyradiculoneuropathy: a possibly treatable sensory ataxia publication-title: Neurology – volume: 7 year: 2020 article-title: Antibodies to neurofascin, contactin‐1, and contactin‐associated protein 1 in CIDP: clinical relevance of IgG isotype publication-title: Neurol Neuroimmunol Neuroinflamm – volume: 266 start-page: 461 year: 2019 end-page: 467 article-title: Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy publication-title: J Neurol – volume: 248 start-page: 772 year: 2001 end-page: 777 article-title: Pure motor chronic inflammatory demyelinating polyneuropathy publication-title: J Neurol – volume: 185 start-page: 119 year: 2001 end-page: 122 article-title: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis publication-title: J Neurol Sci – volume: 24 start-page: S74 issue: suppl 2 year: 2019 end-page: S85 article-title: Immune checkpoint inhibitors‐induced neuromuscular toxicity: from pathogenesis to treatment publication-title: J Peripher Nerv Syst – volume: 15 start-page: 164 year: 2010 end-page: 175 article-title: Peripheral Nerve Society guideline on processing and evaluation of nerve biopsies publication-title: J Peripher Nerv Syst – volume: 24 start-page: 174 year: 2019 end-page: 179 article-title: Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy publication-title: J Peripher Nerv Syst – volume: 342 start-page: 182 year: 2014 end-page: 185 article-title: Diagnostic value of MR imaging in the Lewis‐Sumner syndrome: a case series publication-title: J Neurol Sci – volume: 8 start-page: 285 year: 2019 end-page: 288 article-title: Compliance with international guidelines for chronic inflammatory neuropathies publication-title: Eur J Neurol – volume: 54 start-page: 615 year: 2000 end-page: 620 article-title: Distal acquired demyelinating symmetric neuropathy publication-title: Neurology – volume: 43 start-page: 2202 year: 1993 end-page: 2209 article-title: Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy publication-title: Neurology – start-page: 612 year: 2014 end-page: 614 – volume: 257 start-page: 913 year: 2010 end-page: 919 article-title: Alemtuzumab in the treatment of IVIG‐dependent chronic inflammatory demyelinating polyneuropathy publication-title: J Neurol – volume: 73 start-page: 294 year: 2015 end-page: 302 article-title: Natalizumab as a disease‐modifying therapy in chronic inflammatory demyelinating polyneuropathy—a report of three cases publication-title: Eur Neurol – volume: 58 start-page: 1856 year: 2002 end-page: 1858 article-title: High‐dose cyclophosphamide without stem‐cell rescue for refractory CIDP publication-title: Neurology – volume: 119 start-page: 765 year: 1996 end-page: 774 article-title: Focal upper limb demyelinating neuropathy publication-title: Brain – volume: 190 start-page: 121 year: 2007 end-page: 126 article-title: High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients publication-title: J Neuroimmunol – volume: 25 start-page: 162 year: 2020 end-page: 170 article-title: Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics, electrophysiological study, and response to treatment publication-title: J Peripher Nerv Syst – volume: 17 start-page: 289 year: 2010 end-page: 294 article-title: A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Eur J Neurol – volume: 264 start-page: 243 year: 2017 end-page: 253 article-title: Peripheral nerve ultrasound scoring systems: benchmarking and comparative analysis publication-title: J Neurol – volume: 11 start-page: 493 year: 2012 end-page: 502 article-title: Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial publication-title: Lancet Neurol – volume: 63 start-page: 715 year: 2004 end-page: 717 article-title: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy publication-title: Neurology – volume: 65 start-page: 1924 year: 2005 end-page: 1929 article-title: Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP publication-title: Neurology – volume: 2 start-page: 960 year: 2015 end-page: 971 article-title: Characterization of IgG4 anti‐neurofascin 155 antibody‐positive polyneuropathy publication-title: Ann Clin Transl Neurol – volume: 17 start-page: 356 year: 2010 end-page: 363 article-title: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision publication-title: Eur J Neurol – volume: 14 year: 2014 article-title: Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern publication-title: BMC Neurol – volume: 82 start-page: 306 year: 2011 end-page: 308 article-title: Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature publication-title: J Neurol Neurosurg Psychiatry – volume: 57 start-page: 391 year: 2006 end-page: 395 article-title: Sural nerve donor‐site morbidity: thirty‐four years of follow‐up publication-title: Ann Plast Surg – volume: 77 start-page: 333 year: 2015 end-page: 337 article-title: Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy publication-title: Ann Neurol – volume: 17 start-page: 127 year: 2017 article-title: Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long‐lasting case of chronic immune sensory polyradiculopathy publication-title: BMC Neurol – volume: 95 start-page: e1745 year: 2020 end-page: e1753 article-title: Nerve ultrasound for diagnosing chronic inflammatory neuropathy: a multicenter validation study publication-title: Neurology – volume: 101 start-page: 234 year: 2001 end-page: 238 article-title: Massive peripheral nerve hypertrophy in a patient with multifocal upper limb demyelinating neuropathy (Lewis‐Sumner syndrome) publication-title: Acta Neurol Belg – volume: 8 year: 2018 article-title: Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: a systematic review and meta‐analysis publication-title: Brain Behav – volume: 29 start-page: 748 year: 2004 end-page: 749 article-title: Mycophenolate mofetil in dysimmune neuropathies: a preliminary study publication-title: Muscle Nerve – volume: 122 start-page: 1383 year: 1999 end-page: 1390 article-title: Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy publication-title: Brain – volume: 76 start-page: 89 year: 2016 end-page: 98 article-title: GRADE Working Group. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health publication-title: J Clin Epidemiol – volume: 260 start-page: 3115 year: 2013 end-page: 3121 article-title: Ultrasound of inherited vs. acquired demyelinating polyneuropathies publication-title: J Neurol – volume: 60 start-page: 180 year: 2019 end-page: 183 article-title: Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis publication-title: Muscle Nerve – year: 2013 – volume: 24 start-page: 1307 year: 2017 end-page: 1313 article-title: A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy publication-title: Eur J Neurol – volume: 81 start-page: 1374 year: 2010 end-page: 1379 article-title: Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Neurol Neurosurg Psychiatry – volume: 86 start-page: 800 year: 2016 end-page: 807 article-title: Neurofascin‐155 IgG4 in chronic inflammatory demyelinating polyneuropathy publication-title: Neurology – volume: 86 start-page: 729 year: 2015 end-page: 734 article-title: Frequency and time to relapse after discontinuing 6‐month therapy with IVIg or pulsed methylprednisolone in CIDP publication-title: J Neurol Neurosurg Psychiatry – volume: 85 start-page: 901 year: 2014 end-page: 906 article-title: Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal publication-title: J Neurol Neurosurg Psychiatry – volume: 77 start-page: 544 year: 2006 end-page: 547 article-title: Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate publication-title: J Neurol Neurosurg Psychiatry – volume: 39 start-page: 206 year: 2009 end-page: 220 article-title: Lewis‐Sumner syndrome of pure upper‐limb onset: diagnostic, prognostic, and therapeutic features publication-title: Muscle Nerve – volume: 38 start-page: 2165 year: 2017 end-page: 2169 article-title: Chronic demyelinating neuropathy with anti‐myelin‐associated glycoprotein antibody without any detectable M‐protein publication-title: Neurol Sci – volume: 139 start-page: 2617 year: 2016 end-page: 2630 article-title: Auto‐antibodies to contactin‐associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy publication-title: Brain – volume: 161 start-page: 1228 year: 2005 end-page: 1231 article-title: Autonomic nervous system involvement in chronic inflammatory demyelinating polyneuropathy publication-title: Rev Neurol (Paris) – volume: 22 start-page: 560 year: 1999 end-page: 566 article-title: Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis‐Sumner syndrome publication-title: Muscle Nerve – volume: 51 start-page: 932 year: 2015 end-page: 933 article-title: Which criteria for research in CIDP? An analysis of current practice publication-title: Muscle Nerve – volume: 57 start-page: 542 year: 2018 end-page: 549 article-title: Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis publication-title: Muscle Nerve – volume: 54 start-page: 26 year: 2000 end-page: 32 article-title: Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? publication-title: Neurology – volume: 314 start-page: 461 year: 1986 end-page: 465 article-title: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: N Engl J Med – volume: 16 start-page: 262 year: 1993 end-page: 266 article-title: Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders publication-title: Muscle Nerve – volume: 1 year: 2017 article-title: Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews publication-title: Cochrane Database Syst Rev – volume: 27 start-page: 427 year: 1976 end-page: 458 article-title: Chronic relapsing polyneuritis publication-title: J Neurol Sci – volume: 261 start-page: 1485 year: 2014 end-page: 1491 article-title: Comparison of monoclonal gammopathy of undetermined significance‐associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients publication-title: J Neurol – volume: 8 start-page: 55 year: 1997 end-page: 57 article-title: Massive nerve root hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Assoc Acad Minor Phys – volume: 210 start-page: 19 year: 2003 end-page: 21 article-title: Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy publication-title: J Neurol Sci – volume: 82 start-page: 879 year: 2014 end-page: 886 article-title: Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg publication-title: Neurology – volume: 31 start-page: 526 year: 2018 end-page: 533 article-title: Nerve ultrasound and magnetic resonance imaging in the diagnosis of neuropathy publication-title: Curr Opin Neurol – volume: 2 start-page: 362 year: 1997 end-page: 369 article-title: Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy publication-title: J Peripher Nerv Syst – volume: 2 year: 2015 article-title: Rituximab in treatment‐resistant CIDP with antibodies against paranodal proteins publication-title: Neurol Neuroimmunol Neuroinflamm – volume: 20 start-page: 748 year: 2013 end-page: 755 article-title: Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG—the ICE study publication-title: Eur J Neurol – volume: 24 start-page: S52 issue: suppl 2 year: 2019 end-page: S62 article-title: Bortezomib and other proteosome inhibitors‐induced peripheral neurotoxicity: from pathogenesis to treatment publication-title: J Peripher Nerv Syst – volume: 50 start-page: 480 year: 1998 end-page: 484 article-title: A prospective quantitative study of sensory deficits after whole sural nerve biopsies in diabetic and nondiabetic patients. Surgical approach and the role of collateral sprouting publication-title: Neurology – volume: 138 start-page: 1484 year: 2015 end-page: 1491 article-title: Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia publication-title: Brain – volume: 9 start-page: 245 year: 2010 end-page: 253 article-title: Pulsed high‐dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double‐blind, randomised, controlled trial publication-title: Lancet Neurol – volume: 50 start-page: 40 year: 2014 end-page: 46 article-title: Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy publication-title: Muscle Nerve – volume: 131 start-page: 859 year: 2020 end-page: 865 article-title: Nerve ultrasound reference data in children from two to seven years publication-title: Clin Neurophysiol – volume: 81 start-page: 516 year: 1990 end-page: 521 article-title: Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years publication-title: Acta Neurol Scand – volume: 23 start-page: 283 year: 2000 end-page: 288 article-title: Chronic demyelinating hypertrophic brachial plexus neuropathy publication-title: Muscle Nerve – year: 2020 article-title: Relevance of diagnostic investigations in chronic inflammatory demyelinating polyradiculoneuropathy: data from the Italian CIDP database publication-title: J Peripher Nerv Syst – volume: 86 start-page: 1331 year: 2015 end-page: 1336 article-title: Intravenous immunoglobulin response in treatment‐naïve chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Neurol Neurosurg Psychiatry – volume: 264 start-page: 2010 year: 2017 end-page: 2020 article-title: Severe refractory CIDP: a case series of 10 patients treated with bortezomib publication-title: J Neurol – volume: 78 start-page: 1271 year: 2007 end-page: 1272 article-title: Complications following sural and peroneal nerve biopsies publication-title: J Neurol Neurosurg Psychiatry – volume: 119 start-page: 1055 year: 1996 end-page: 1066 article-title: Plasma‐exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double‐blind, sham‐controlled, cross‐over study publication-title: Brain – volume: 80 start-page: 1364 year: 2009 end-page: 1368 article-title: Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study publication-title: J Neurol Neurosurg Psychiatry – volume: 182 start-page: E839 year: 2010 end-page: E842 article-title: AGREE II: advancing guideline development, reporting and evaluation in health care publication-title: CMAJ – volume: 62 start-page: 220 year: 2009 end-page: 222 article-title: A modified approach to sural nerve biopsy: minimizing complications publication-title: Ann Plast Surg – volume: 23 start-page: 73 year: 2000 end-page: 79 article-title: Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy publication-title: Muscle Nerve – volume: 58 start-page: 542 year: 2010 end-page: 548 article-title: Sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy: are supportive pathologic criteria useful in diagnosis? publication-title: Neurol India – volume: 89 start-page: 1145 year: 2018 end-page: 1151 article-title: Neurofascin‐155 IgM autoantibodies in patients with inflammatory neuropathies publication-title: J Neurol Neurosurg Psychiatry – volume: 53 start-page: 57 year: 1999 end-page: 61 article-title: Randomized trial of interferon beta‐1a in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Neurology – volume: 96 start-page: e1876 year: 2021 end-page: e1886 article-title: Quantifying treatment‐related fluctuations in CIDP: results of the GRIPPER study publication-title: Neurology – volume: 14 start-page: 162 year: 2015 end-page: 173 article-title: Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis publication-title: Lancet Neurol – volume: 17 start-page: 1113 year: 2010 end-page: e88 article-title: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision publication-title: Eur J Neurol – volume: 6 year: 2019 article-title: Anti–pan‐neurofascin IgG3 as a marker of fulminant autoimmune neuropathy publication-title: Neurol Neuroimmunol Neuroinflamm – volume: 69 start-page: 1043 year: 2011 end-page: 1054 article-title: Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus neuropathy? publication-title: Ann Neurol – volume: 277 start-page: 1 year: 2009 end-page: 8 article-title: Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy publication-title: J Neurol Sci – volume: 140 start-page: 1851 year: 2017 end-page: 1858 article-title: Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy publication-title: Brain – volume: 246 start-page: 1134 year: 1999 end-page: 1139 article-title: Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long‐term follow‐up study publication-title: J Neurol – volume: 51 start-page: 549 year: 2015 end-page: 553 article-title: Comparison of 2‐limb versus 3‐limb electrodiagnostic studies in the evaluation of chronic inflammatory demyelinating polyneuropathy publication-title: Muscle Nerve – volume: 14 start-page: 118 year: 2009 end-page: 124 article-title: Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy publication-title: J Peripher Nerv Syst – volume: 33 start-page: 317 year: 2005 end-page: 324 article-title: A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy publication-title: Transfus Apher Sci – volume: 246 start-page: 93 year: 1999 end-page: 96 article-title: Clinical outcome of sural nerve biopsy: a retrospective study publication-title: J Neurol – volume: 83 start-page: 476 year: 2012 end-page: 479 article-title: Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy publication-title: J Neurol Neurosurg Psychiatry – volume: 144 start-page: 1183 year: 2021 end-page: 1196 article-title: Antibodies to the Caspr1/contactin‐1 complex in chronic inflammatory demyelinating polyneuropathy publication-title: Brain – volume: 224 start-page: 29 year: 2004 end-page: 35 article-title: Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Neurol Sci – volume: 94 start-page: e1470 year: 2020 end-page: e1479 article-title: Nerve ultrasound improves detection of treatment‐responsive chronic inflammatory neuropathies publication-title: Neurology – volume: 345 year: 2020 article-title: Sensitivity and specificity of a commercial ELISA test for anti‐MAG antibodies in patients with neuropathy publication-title: J Neuroimmunol – volume: 56 start-page: 37 year: 2006 end-page: 38 article-title: Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: an open‐label study publication-title: Eur Neurol – volume: 20 start-page: 1569 year: 1997 end-page: 1575 article-title: Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long‐term follow‐up, with comparison to adults publication-title: Muscle Nerve – volume: 74 start-page: 651 year: 2010 end-page: 657 article-title: Intramuscular interferon beta‐1a in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Neurology – volume: 55 start-page: 476 year: 2017 end-page: 482 article-title: Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy publication-title: Muscle Nerve – volume: 85 start-page: 618 year: 2014 end-page: 624 article-title: Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP publication-title: J Neurol Neurosurg Psychiatry – volume: 51 start-page: 1735 year: 1998 end-page: 1738 article-title: Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy publication-title: Neurology – volume: 78 start-page: 1079 year: 2012 end-page: 1084 article-title: Long‐term remission of CIDP after pulsed dexamethasone or short‐term prednisolone treatment publication-title: Neurology – volume: 18 start-page: 130 year: 2013 end-page: 140 article-title: Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single‐arm, open‐label phase III study (the PRIMA study) publication-title: J Peripher Nerv Syst – volume: 7 start-page: 136 year: 2008 end-page: 144 article-title: Intravenous immune globulin (10% caprylate‐chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo‐controlled trial publication-title: Lancet Neurol – volume: 4 start-page: 1051 year: 2018 end-page: 1060 article-title: Ultrastructural mechanisms of macrophage‐induced demyelination in CIDP publication-title: Neurology – volume: 10 start-page: 398 year: 2000 end-page: 406 article-title: Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long‐term outcome publication-title: Neuromuscul Disord – volume: 52 start-page: 498 year: 1999 end-page: 503 article-title: Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy publication-title: Neurology – volume: 21 start-page: 33 year: 2016 end-page: 37 article-title: A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies publication-title: J Peripher Nerv Syst – volume: 17 start-page: 1 year: 2015 end-page: 5 article-title: Fludarabine in the treatment of refractory chronic inflammatory demyelinating neuropathies publication-title: J Clin Neuromuscul Dis – volume: 61 start-page: 36 year: 1996 end-page: 42 article-title: Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients publication-title: J Neurol Neurosurg Psychiatry – volume: 67 start-page: 175 year: 2006 end-page: 176 article-title: Hypoglossal neuropathy in Lewis‐Sumner syndrome masquerading as motor neuron disease publication-title: Neurology – volume: 74 start-page: 1680 year: 2010 end-page: 1686 article-title: Distinguishing acute‐onset CIDP from fluctuating Guillain‐Barré syndrome publication-title: Neurology – volume: 21 start-page: 85 year: 2016 end-page: 87 article-title: Fampridine‐PR (prolonged released 4‐aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system publication-title: J Peripher Nerv Syst – volume: 57 start-page: 875 year: 2018 end-page: 883 article-title: Chronic inflammatory demyelinating polyneuropathy and malignancy: a systematic review publication-title: Muscle Nerve – volume: 22 start-page: 1505 year: 2015 end-page: 1510 article-title: Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN TFs publication-title: Eur J Neurol – volume: 24 start-page: 412 year: 2017 end-page: 418 article-title: Subcutaneous immunoglobulin as first‐line therapy in treatment‐naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study publication-title: Eur J Neurol – volume: 10 start-page: 158 year: 2005 end-page: 173 article-title: History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation publication-title: J Peripher Nerv Syst – volume: 252 start-page: 1235 year: 2005 end-page: 1237 article-title: Chronic inflammatory demyelinating polyneuropathy and respiratory failure publication-title: J Neurol – volume: 88 start-page: 143 year: 2017 end-page: 151 article-title: Diagnostic value of sonography in treatment‐naive chronic inflammatory neuropathies publication-title: Neurology – volume: 60 start-page: 757 year: 2019 end-page: 761 article-title: Nerve ultrasound normal values in children and young adults publication-title: Muscle Nerve – volume: 85 start-page: 498 year: 2015 end-page: 504 article-title: CIDP diagnostic pitfalls and perception of treatment benefit publication-title: Neurology – volume: 2015 issue: 8 year: 2015 article-title: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Cochrane Database Syst Rev – volume: 10 start-page: 11 year: 2005 end-page: 16 article-title: High‐dose cyclophosphamide results in long‐term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy publication-title: J Peripher Nerv Syst – volume: 54 start-page: 2 year: 2016 end-page: 15 article-title: Adverse events in apheresis: an update of the WAA registry data publication-title: Transfus Apher Sci – volume: 32 start-page: 486 year: 2017 end-page: 493 article-title: A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinatingpolyneuropathy publication-title: J Clin Apher – volume: 57 start-page: 1745 year: 2000 end-page: 1750 article-title: Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria publication-title: Arch Neurol – volume: 94 start-page: e62 year: 2020 end-page: e74 article-title: Diagnostic accuracy of MRI and ultrasound in chronic immune‐mediated neuropathies publication-title: Neurology – volume: 18 start-page: 1417 year: 2011 end-page: 1421 article-title: Italian Network for CIDP Register. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis publication-title: Eur J Neurol – volume: 81 start-page: 1194 year: 2010 end-page: 1199 article-title: Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance publication-title: J Neurol Neurosurg Psychiatry – volume: 360 start-page: 170 year: 2016 end-page: 175 article-title: Contribution of plexus MRI in the diagnosis of atypical chronic inflammatory demyelinating polyneuropathies publication-title: J Neurol Sci – volume: 126 start-page: 1805 year: 2015 end-page: 1810 article-title: Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: a Japanese‐European multicenter prospective study publication-title: Clin Neurophysiol – volume: 264 start-page: 1011 year: 2017 end-page: 1014 article-title: Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases publication-title: J Neurol – volume: 157 start-page: 1887 year: 2016 end-page: 1894 article-title: Pain in acquired inflammatory demyelinating polyneuropathies publication-title: Pain – volume: 27 start-page: 181 year: 2020 end-page: 187 article-title: Prospective study of the additional benefit of plexus magnetic resonance imaging in the diagnosis of chronic inflammatory demyelinating polyneuropathy publication-title: Eur J Neurol – volume: 27 start-page: 497 year: 2003 end-page: 499 article-title: Phrenic nerve palsy as a feature of chronic inflammatory demyelinating polyneuropathy publication-title: Muscle Nerve – volume: 66 start-page: 726 year: 2013 end-page: 735 article-title: GRADE guidelines: 15. Going from evidence to recommendation‐determinants of a recommendation's direction and strength publication-title: J Clin Epidemiol – volume: 68 start-page: 1622 year: 2007 end-page: 1629 article-title: Classifications and treatment responses in chronic immune‐mediated demyelinating polyneuropathy publication-title: Neurology – volume: 39 start-page: 386 year: 2009 end-page: 388 article-title: Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient publication-title: Muscle Nerve – volume: 86 start-page: 720 year: 2015 end-page: 728 article-title: Destruction of paranodal architecture in inflammatory neuropathy with anti‐contactin‐1 autoantibodies publication-title: J Neurol Neurosurg Psychiatry – volume: 76 start-page: 1115 year: 2005 end-page: 1120 article-title: Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin publication-title: J Neurol Neurosurg Psychiatry – volume: 38 start-page: 1599 year: 2008 end-page: 1603 article-title: Sensory nerve conduction slowing is a specific marker for CIDP publication-title: Muscle Nerve – volume: 17 start-page: 689 year: 2018 end-page: 698 article-title: Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double‐blind, multicentre, randomised controlled trial publication-title: Lancet Neurol – volume: 22 start-page: 425 year: 2017 end-page: 432 article-title: Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Peripher Nerv Syst – volume: 31 start-page: 628 year: 2005 end-page: 632 article-title: Sural and radial sensory responses in healthy adults: diagnostic implications for polyneuropathy publication-title: Muscle Nerve – volume: 92 start-page: 172 year: 2021 end-page: 176 article-title: Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs publication-title: J Neurol Neurosurg Psychiatry – volume: 55 start-page: 677 year: 1992 end-page: 680 article-title: Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy publication-title: J Neurol Neurosurg Psychiatry – issue: 12 year: 2013 article-title: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Cochrane Database Syst Rev – volume: 49 start-page: 253 year: 1997 end-page: 257 article-title: Assessment of hand function in a patient with chronic sensory demyelinating neuropathy publication-title: Neurology – volume: 24 start-page: 180 year: 2019 end-page: 186 article-title: One‐year follow‐up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Peripher Nerv Syst – volume: 65 start-page: 138 year: 2005 end-page: 140 article-title: Distinguishing acute‐onset CIDP from Guillain‐Barré syndrome with treatment related fluctuations publication-title: Neurology – volume: 3 year: 2013 article-title: MRI of the cervical nerve roots in the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy: a single‐institution, retrospective case‐control study publication-title: BMJ Open – volume: 21 start-page: 454 year: 1998 end-page: 460 article-title: Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Muscle Nerve – volume: 80 start-page: 3 year: 2016 end-page: 7 article-title: Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group publication-title: J Clin Epidemiol – volume: 76 start-page: 337 year: 2011 end-page: 345 article-title: Rasch‐built Overall Disability Scale (R‐ODS) for immune‐mediated peripheral neuropathies publication-title: Neurology – volume: 15 start-page: 50 year: 2010 end-page: 56 article-title: A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Periph Nerv Syst – volume: 27 start-page: 478 year: 2003 end-page: 485 article-title: Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases publication-title: Muscle Nerve – volume: 56 start-page: 94 year: 2001 end-page: 96 article-title: Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases publication-title: Neurology – volume: 184 start-page: 57 year: 2001 end-page: 63 article-title: Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy publication-title: J Neurol Sci – volume: 77 start-page: 114 year: 2006 end-page: 116 article-title: Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Neurol Neurosurg Psychiatry – volume: 13 start-page: 149 year: 2012 end-page: 152 article-title: Chronic inflammatory pure sensory polyradiculoneuropathy: a rare CIDP variant with unusual electrophysiology publication-title: J Clin Neuromuscul Dis – volume: 13 start-page: 326 year: 2006 end-page: 332 article-title: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society publication-title: Eur J Neurol – volume: 18 start-page: 899 year: 2011 end-page: 905 article-title: Non‐anti‐MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases publication-title: Eur J Neurol – volume: 90 start-page: 125 year: 2019 end-page: 132 article-title: Italian CIDP Database study group. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database publication-title: J Neurol Neurosurg Psychiatry – volume: 35 start-page: 1173 year: 1985 end-page: 1176 article-title: Combined azathioprine and prednisone in chronic inflammatory‐demyelinating polyneuropathy publication-title: Neurology – volume: 6 year: 2019 article-title: Long‐term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study publication-title: Neurol Neuroimmunol Neuroinflamm – volume: 14 start-page: 353 year: 1997 end-page: 356 article-title: Persistent postoperative complaints after whole sural nerve biopsies in diabetic and non‐diabetic subjects publication-title: Diabet Med – volume: 73 start-page: 370 year: 2013 end-page: 380 article-title: Antibodies to contactin‐1 in chronic inflammatory demyelinating polyneuropathy publication-title: Ann Neurol – volume: 260 start-page: 2052 year: 2013 end-page: 2056 article-title: Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? publication-title: J Neurol – volume: 25 start-page: 356 year: 2020 end-page: 365 article-title: An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study publication-title: J Peripher Nerv Syst – volume: 90 start-page: 138 year: 2019 end-page: 140 article-title: Expanded teased nerve fibre pathological conditions in disease association publication-title: J Neurol Neurosurg Psychiatry – volume: 61 start-page: 649 year: 2020 end-page: 653 article-title: Sonographic measurements of normal C5‐C8 nerve roots in children publication-title: Muscle Nerve – volume: 48 start-page: 874 year: 1997 end-page: 877 article-title: Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinating polyneuropathy publication-title: Neurology – volume: 67 start-page: 802 year: 2010 end-page: 807 article-title: Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Arch Neurol – volume: 18 start-page: 327 year: 2015 end-page: 330 article-title: Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: challenges, controversies and questions publication-title: Ann Indian Acad Neurol – volume: 118 start-page: 1999 year: 2007 end-page: 2004 article-title: The value of sensory electrophysiology in chronic inflammatory demyelinating polyneuropathy publication-title: Clin Neurophysiol – volume: 20 start-page: 397 year: 2015 end-page: 402 article-title: Anti‐TNF alpha medications and neuropathy publication-title: J Peripher Nerv Syst – volume: 14 start-page: 399 year: 2014 end-page: 408 article-title: CIDP: mimics and chameleons publication-title: Pract Neurol – volume: 20 start-page: 836 year: 2013 end-page: 842 article-title: Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Eur J Neurol – volume: 33 start-page: 78 year: 2006 end-page: 84 article-title: Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Muscle Nerve – volume: 48 start-page: 727 year: 2013 end-page: 732 article-title: Sensory chronic inflammatory demyelinating polyneuropathy: an under‐recognized entity? publication-title: Muscle Nerve – volume: 50 start-page: 84 year: 1998 end-page: 87 article-title: Treatment of chronic inflammatory demyelinating polyneuropathy with interferon‐alpha 2a publication-title: Neurology – volume: 54 start-page: 943 year: 2000 end-page: 949 article-title: Psychometric evaluation of a new sensory scale in immune‐mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group publication-title: Neurology – volume: 41 start-page: 202 year: 2010 end-page: 207 article-title: Clinical and electrophysiological parameters distinguishing acute‐onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy publication-title: Muscle Nerve – volume: 9 start-page: 6155 year: 2019 article-title: Clinical and laboratory features of anti‐MAG neuropathy without monoclonal gammopathy publication-title: Sci Rep – volume: 31 start-page: 108 year: 2005 end-page: 112 article-title: Chronic inflammatory demyelinating polyradiculoneuropathy with autonomic involvement publication-title: Muscle Nerve – volume: 15 start-page: 295 year: 2010 end-page: 301 article-title: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision publication-title: J Peripher Nerv Syst – volume: 353 year: 2016 article-title: GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines publication-title: BMJ – volume: 47 start-page: 98 year: 1996 end-page: 102 article-title: Childhood chronic inflammatory demyelinating neuropathies: clinical course and long‐term follow‐up publication-title: Neurology – volume: 61 start-page: 182 year: 2019 end-page: 186 article-title: Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy publication-title: Muscle Nerve – volume: 11 start-page: 136 year: 1982 end-page: 141 article-title: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment publication-title: Ann Neurol – year: 1943 – volume: 32 start-page: 958 year: 1982 end-page: 964 article-title: Multifocal demyelinating neuropathy with persistent conduction block publication-title: Neurology – volume: 5 start-page: 499 year: 2018 end-page: 501 article-title: Head and voice tremor improving with immunotherapy in an anti‐NF155 positive CIDP patient publication-title: Ann Clin Transl Neurol – volume: 10 year: 2016 article-title: Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_102_1 doi: 10.1111/j.1085-9489.2005.0010206.x – ident: e_1_2_8_181_1 doi: 10.1016/S1474-4422(08)70299-0 – ident: e_1_2_8_26_1 doi: 10.1016/S0035-3787(05)85198-7 – ident: e_1_2_8_12_1 doi: 10.1212/WNL.0000000000001833 – ident: e_1_2_8_30_1 doi: 10.1016/S0960-8966(00)00119-X – ident: e_1_2_8_143_1 doi: 10.1002/(SICI)1096-9136(199705)14:5<353::AID-DIA343>3.0.CO;2-E – ident: e_1_2_8_144_1 doi: 10.1136/jnnp.2007.116368 – ident: e_1_2_8_4_1 doi: 10.1111/j.1529-8027.2010.00245.x – ident: e_1_2_8_224_1 doi: 10.1007/s40122-019-0128-y – ident: e_1_2_8_124_1 doi: 10.1016/j.jns.2015.11.048 – ident: e_1_2_8_172_1 doi: 10.1002/ana.410360607 – ident: e_1_2_8_200_1 doi: 10.1212/WNL.51.6.1735 – ident: e_1_2_8_55_1 doi: 10.1111/j.1529-8027.2010.00290.x – ident: e_1_2_8_184_1 doi: 10.1136/jnnp.2005.074781 – ident: e_1_2_8_16_1 doi: 10.1503/cmaj.090449 – volume: 24 start-page: S74 issue: 2 year: 2019 ident: e_1_2_8_84_1 article-title: Immune checkpoint inhibitors‐induced neuromuscular toxicity: from pathogenesis to treatment publication-title: J Peripher Nerv Syst – ident: e_1_2_8_208_1 doi: 10.1007/s00415-017-8462-7 – ident: e_1_2_8_214_1 doi: 10.1002/jca.21546 – ident: e_1_2_8_57_1 doi: 10.1186/1471-2377-14-72 – ident: e_1_2_8_206_1 doi: 10.1136/jnnp.2009.188912 – ident: e_1_2_8_218_1 doi: 10.1159/000381767 – ident: e_1_2_8_127_1 doi: 10.1002/mus.26821 – ident: e_1_2_8_65_1 doi: 10.1186/s12883-017-0906-2 – volume: 2 start-page: 362 year: 1997 ident: e_1_2_8_45_1 article-title: Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy publication-title: J Peripher Nerv Syst – ident: e_1_2_8_122_1 doi: 10.1097/WCO.0000000000000607 – ident: e_1_2_8_63_1 doi: 10.1212/01.WNL.0000142507.12763.58 – ident: e_1_2_8_23_1 doi: 10.1007/s00415-005-0848-2 – ident: e_1_2_8_115_1 doi: 10.1212/WNL.0000000000010369 – ident: e_1_2_8_138_1 doi: 10.4103/0028-3886.68673 – ident: e_1_2_8_64_1 doi: 10.1097/CND.0b013e31822484fb – ident: e_1_2_8_211_1 doi: 10.1016/S0022-510X(03)00010-8 – ident: e_1_2_8_99_1 doi: 10.1136/jnnp.2009.194324 – ident: e_1_2_8_114_1 doi: 10.1212/WNL.0000000000008978 – ident: e_1_2_8_190_1 doi: 10.1212/WNL.56.1.94 – ident: e_1_2_8_25_1 doi: 10.1002/mus.20140 – ident: e_1_2_8_21_1 doi: 10.1016/j.jclinepi.2016.07.006 – ident: e_1_2_8_191_1 doi: 10.1212/WNL.35.8.1173 – ident: e_1_2_8_177_1 doi: 10.1056/NEJM198602203140801 – ident: e_1_2_8_103_1 doi: 10.1111/j.1468-1331.2012.03851.x – volume-title: GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations year: 2013 ident: e_1_2_8_6_1 – ident: e_1_2_8_52_1 doi: 10.1002/(SICI)1097-4598(200002)23:2<283::AID-MUS23>3.0.CO;2-Q – ident: e_1_2_8_203_1 doi: 10.1136/jnnp.60.2.185 – ident: e_1_2_8_5_1 doi: 10.1111/j.1468-1331.2009.02930.x – ident: e_1_2_8_39_1 doi: 10.1136/jnnp.61.1.36 – ident: e_1_2_8_147_1 doi: 10.1007/s00415-014-7357-0 – ident: e_1_2_8_212_1 doi: 10.1111/jns.12169 – ident: e_1_2_8_111_1 doi: 10.1212/WNL.0000000000003483 – ident: e_1_2_8_170_1 doi: 10.1007/s00415-018-9157-4 – ident: e_1_2_8_222_1 doi: 10.1016/S1474-4422(14)70251-0 – ident: e_1_2_8_88_1 doi: 10.1016/j.clinph.2014.11.027 – ident: e_1_2_8_13_1 doi: 10.1002/mus.25271 – ident: e_1_2_8_117_1 doi: 10.1016/j.clinph.2019.12.404 – ident: e_1_2_8_140_1 doi: 10.1136/jnnp.64.1.84 – volume: 24 start-page: S52 issue: 2 year: 2019 ident: e_1_2_8_85_1 article-title: Bortezomib and other proteosome inhibitors‐induced peripheral neurotoxicity: from pathogenesis to treatment publication-title: J Peripher Nerv Syst – ident: e_1_2_8_98_1 doi: 10.1136/jnnp.72.5.596 – ident: e_1_2_8_130_1 doi: 10.1002/mus.26028 – ident: e_1_2_8_136_1 doi: 10.1212/01.wnl.0000188879.19900.b7 – ident: e_1_2_8_215_1 doi: 10.1016/j.transci.2005.07.010 – ident: e_1_2_8_167_1 doi: 10.1016/S1474-4422(12)70093-5 – ident: e_1_2_8_91_1 doi: 10.1016/j.clinph.2007.06.014 – ident: e_1_2_8_43_1 doi: 10.1002/(SICI)1097-4598(199905)22:5<560::AID-MUS2>3.0.CO;2-Q – ident: e_1_2_8_53_1 doi: 10.1136/jnnp.57.7.778 – ident: e_1_2_8_60_1 doi: 10.1002/mus.880180411 – ident: e_1_2_8_110_1 doi: 10.1111/ene.13380 – ident: e_1_2_8_97_1 doi: 10.1002/mus.26747 – ident: e_1_2_8_180_1 doi: 10.1016/j.transci.2016.01.003 – ident: e_1_2_8_54_1 doi: 10.1007/s004150170093 – ident: e_1_2_8_162_1 doi: 10.1016/S1474-4422(07)70329-0 – ident: e_1_2_8_166_1 doi: 10.1001/archneurol.2010.105 – ident: e_1_2_8_189_1 doi: 10.1002/mus.20024 – ident: e_1_2_8_153_1 doi: 10.1136/jnnp-2020-324012 – ident: e_1_2_8_226_1 doi: 10.1111/jns.12318 – ident: e_1_2_8_160_1 doi: 10.1016/S1474-4422(10)70021-1 – ident: e_1_2_8_96_1 doi: 10.1016/S1474-4422(17)30378-2 – ident: e_1_2_8_44_1 doi: 10.1212/WNL.54.1.26 – volume: 1 start-page: CD010369 year: 2017 ident: e_1_2_8_106_1 article-title: Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews publication-title: Cochrane Database Syst Rev – volume-title: Aids to the Investigation of the Peripheral Nervous System year: 1943 ident: e_1_2_8_100_1 – ident: e_1_2_8_11_1 doi: 10.1212/WNL.0b013e31824e8f84 – ident: e_1_2_8_68_1 doi: 10.1002/ana.23794 – ident: e_1_2_8_168_1 doi: 10.1111/jns.12242 – ident: e_1_2_8_194_1 doi: 10.1159/000095139 – ident: e_1_2_8_193_1 doi: 10.1016/S0022-510X(01)00478-6 – ident: e_1_2_8_149_1 doi: 10.1212/WNL.43.11.2202 – ident: e_1_2_8_154_1 doi: 10.1016/j.jneuroim.2020.577288 – ident: e_1_2_8_205_1 doi: 10.1136/jnnp.2003.035428 – ident: e_1_2_8_83_1 doi: 10.1111/jns.12147 – ident: e_1_2_8_142_1 doi: 10.1097/01.sap.0000221963.66229.b6 – ident: e_1_2_8_42_1 doi: 10.1212/WNL.32.9.958 – ident: e_1_2_8_165_1 doi: 10.1111/jns.12158 – ident: e_1_2_8_56_1 doi: 10.1111/jns.12380 – ident: e_1_2_8_217_1 doi: 10.4103/0972-2327.160065 – ident: e_1_2_8_225_1 doi: 10.1097/j.pain.0000000000000539 – ident: e_1_2_8_118_1 doi: 10.1002/mus.26826 – ident: e_1_2_8_135_1 doi: 10.1136/jnnp-2018-319077 – ident: e_1_2_8_161_1 doi: 10.1136/jnnp-2013-307515 – ident: e_1_2_8_155_1 doi: 10.1136/jnnp-2018-318170 – ident: e_1_2_8_201_1 doi: 10.1016/0022-510X(76)90213-6 – ident: e_1_2_8_132_1 doi: 10.1111/jns.12378 – ident: e_1_2_8_196_1 doi: 10.1212/WNL.52.3.498 – ident: e_1_2_8_174_1 doi: 10.1212/NXI.0000000000000590 – ident: e_1_2_8_178_1 doi: 10.1093/brain/119.4.1055 – ident: e_1_2_8_119_1 doi: 10.1212/WNL.48.4.874 – ident: e_1_2_8_123_1 doi: 10.1002/ana.24314 – ident: e_1_2_8_195_1 doi: 10.1046/j.1468-1331.2002.00478.x – ident: e_1_2_8_73_1 doi: 10.1212/WNL.0000000000002418 – ident: e_1_2_8_82_1 doi: 10.1007/978-1-4614-6567-6_29 – ident: e_1_2_8_17_1 doi: 10.1111/ene.12818 – ident: e_1_2_8_61_1 doi: 10.1212/WNL.49.1.253 – ident: e_1_2_8_175_1 doi: 10.1111/ene.12080 – ident: e_1_2_8_139_1 doi: 10.1001/archneur.57.12.1745 – ident: e_1_2_8_183_1 doi: 10.1002/mus.21171 – ident: e_1_2_8_33_1 doi: 10.1212/WNL.0b013e3181e07d14 – volume: 101 start-page: 234 year: 2001 ident: e_1_2_8_46_1 article-title: Massive peripheral nerve hypertrophy in a patient with multifocal upper limb demyelinating neuropathy (Lewis‐Sumner syndrome) publication-title: Acta Neurol Belg – ident: e_1_2_8_58_1 doi: 10.1136/jnnp.55.8.677 – ident: e_1_2_8_152_1 doi: 10.1136/practneurol-2014-000831 – ident: e_1_2_8_221_1 doi: 10.1136/jnnp-2013-306014 – ident: e_1_2_8_220_1 doi: 10.1111/j.1529-8027.2009.00221.x – ident: e_1_2_8_219_1 doi: 10.1016/S0041-1345(98)01389-X – ident: e_1_2_8_24_1 doi: 10.1212/WNL.50.4.1179 – ident: e_1_2_8_169_1 doi: 10.1007/s00415-013-6938-7 – ident: e_1_2_8_77_1 doi: 10.1093/brain/awx124 – ident: e_1_2_8_95_1 doi: 10.1212/WNL.0b013e318208824b – ident: e_1_2_8_8_1 doi: 10.1136/jnnp.2009.179358 – ident: e_1_2_8_150_1 doi: 10.1007/s10072-017-3133-0 – ident: e_1_2_8_2_1 doi: 10.1111/j.1085-9489.2005.10302.x – ident: e_1_2_8_62_1 doi: 10.1007/s004150050531 – ident: e_1_2_8_129_1 doi: 10.1136/bmjopen-2013-003443 – ident: e_1_2_8_223_1 doi: 10.1111/j.1468-1331.2010.02999.x – ident: e_1_2_8_137_1 doi: 10.1002/mus.10348 – ident: e_1_2_8_36_1 doi: 10.1111/j.1529-8027.2010.00251.x – ident: e_1_2_8_20_1 doi: 10.1016/j.jclinepi.2013.02.003 – ident: e_1_2_8_145_1 doi: 10.1212/WNL.50.2.480 – ident: e_1_2_8_182_1 doi: 10.1111/j.1468-1331.2011.03495.x – ident: e_1_2_8_209_1 doi: 10.1007/s00415-009-5437-3 – ident: e_1_2_8_29_1 doi: 10.1002/(SICI)1097-4598(199712)20:12<1569::AID-MUS12>3.0.CO;2-W – ident: e_1_2_8_125_1 doi: 10.1111/ene.14053 – ident: e_1_2_8_87_1 doi: 10.1002/mus.24424 – ident: e_1_2_8_109_1 doi: 10.1136/jnnp.2004.056515 – ident: e_1_2_8_202_1 doi: 10.1002/(SICI)1097-4598(199804)21:4<454::AID-MUS3>3.0.CO;2-8 – ident: e_1_2_8_199_1 doi: 10.1016/j.jneuroim.2007.07.005 – ident: e_1_2_8_28_1 doi: 10.1212/WNL.47.1.98 – ident: e_1_2_8_164_1 doi: 10.1111/jns.12408 – ident: e_1_2_8_35_1 doi: 10.1111/j.1600-0404.1990.tb01011.x – ident: e_1_2_8_185_1 doi: 10.1212/WNL.53.1.57 – ident: e_1_2_8_112_1 doi: 10.1007/s00415-016-8305-y – ident: e_1_2_8_204_1 doi: 10.1016/j.jns.2004.05.014 – ident: e_1_2_8_121_1 doi: 10.1016/j.jns.2014.04.033 – ident: e_1_2_8_74_1 doi: 10.1093/brain/aww189 – ident: e_1_2_8_157_1 doi: 10.1002/brb3.1115 – ident: e_1_2_8_148_1 doi: 10.1002/(SICI)1097-4598(200001)23:1<73::AID-MUS9>3.0.CO;2-5 – ident: e_1_2_8_14_1 doi: 10.1002/mus.25997 – ident: e_1_2_8_66_1 doi: 10.1038/nrneurol.2017.84 – ident: e_1_2_8_92_1 doi: 10.1002/mus.20313 – ident: e_1_2_8_128_1 doi: 10.1007/s00415-020-10232-8 – ident: e_1_2_8_163_1 doi: 10.1111/jns5.12017 – ident: e_1_2_8_67_1 doi: 10.3389/fimmu.2018.01029 – ident: e_1_2_8_141_1 doi: 10.1097/SAP.0b013e31817e9c8d – ident: e_1_2_8_134_1 doi: 10.1002/ana.22334 – ident: e_1_2_8_131_1 doi: 10.1002/mus.26488 – ident: e_1_2_8_188_1 doi: 10.1136/jnnp.2009.177576 – ident: e_1_2_8_133_1 doi: 10.1111/j.1529-8027.2010.00276.x – ident: e_1_2_8_31_1 doi: 10.1016/S0022-510X(00)00493-7 – ident: e_1_2_8_50_1 doi: 10.1111/jns.12325 – ident: e_1_2_8_210_1 doi: 10.1007/s00415-017-8599-4 – ident: e_1_2_8_158_1 doi: 10.1002/acn3.539 – ident: e_1_2_8_9_1 doi: 10.1002/mus.24088 – ident: e_1_2_8_79_1 doi: 10.1016/j.nmd.2016.10.008 – ident: e_1_2_8_34_1 doi: 10.1002/mus.21480 – ident: e_1_2_8_116_1 doi: 10.1002/mus.26715 – ident: e_1_2_8_71_1 doi: 10.1212/WNL.0000000000000205 – ident: e_1_2_8_156_1 doi: 10.1038/s41598-019-42545-8 – ident: e_1_2_8_32_1 doi: 10.1212/01.wnl.0000167549.09664.b8 – ident: e_1_2_8_86_1 doi: 10.1111/j.1085-9489.2005.10306.x – ident: e_1_2_8_94_1 doi: 10.1016/j.jns.2008.11.015 – ident: e_1_2_8_187_1 doi: 10.1016/S1474-4422(18)30202-3 – ident: e_1_2_8_126_1 doi: 10.1212/WNL.0000000000008697 – ident: e_1_2_8_69_1 doi: 10.1136/jnnp-2014-309916 – volume: 2015 start-page: CD003906 issue: 8 year: 2015 ident: e_1_2_8_179_1 article-title: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_40_1 doi: 10.1111/j.1468-1331.2010.03312.x – ident: e_1_2_8_47_1 doi: 10.1212/01.wnl.0000223577.69111.2c – ident: e_1_2_8_80_1 doi: 10.1212/WNL.0000000000006625 – ident: e_1_2_8_198_1 doi: 10.1111/j.1085-9489.2005.10104.x – ident: e_1_2_8_37_1 doi: 10.1136/jnnp-2018-318714 – volume: 8 start-page: 55 year: 1997 ident: e_1_2_8_227_1 article-title: Massive nerve root hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: J Assoc Acad Minor Phys – ident: e_1_2_8_105_1 doi: 10.1212/WNL.0000000000011703 – ident: e_1_2_8_76_1 doi: 10.1093/brain/awab014 – ident: e_1_2_8_48_1 doi: 10.1002/mus.21199 – ident: e_1_2_8_101_1 doi: 10.1212/WNL.54.4.943 – ident: e_1_2_8_159_1 doi: 10.1002/ana.410110205 – ident: e_1_2_8_72_1 doi: 10.1002/acn3.248 – ident: e_1_2_8_3_1 doi: 10.1111/j.1468-1331.2006.01278.x – ident: e_1_2_8_120_1 doi: 10.1093/brain/122.7.1383 – ident: e_1_2_8_27_1 doi: 10.1002/mus.20438 – ident: e_1_2_8_19_1 doi: 10.1016/j.jclinepi.2016.01.032 – ident: e_1_2_8_10_1 doi: 10.1002/mus.24496 – ident: e_1_2_8_22_1 doi: 10.1002/mus.10361 – ident: e_1_2_8_146_1 doi: 10.1007/s004150050314 – ident: e_1_2_8_38_1 doi: 10.1212/WNL.54.3.615 – ident: e_1_2_8_104_1 doi: 10.1111/jns.12396 – ident: e_1_2_8_171_1 doi: 10.1136/jnnp.2010.206599 – ident: e_1_2_8_216_1 doi: 10.1212/WNL.50.1.84 – ident: e_1_2_8_75_1 doi: 10.1212/NXI.0000000000000639 – ident: e_1_2_8_213_1 doi: 10.1097/CND.0000000000000083 – volume: 10 start-page: CD002827 year: 2016 ident: e_1_2_8_41_1 article-title: Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies publication-title: Cochrane Database Syst Rev – start-page: CD001797 issue: 12 year: 2013 ident: e_1_2_8_173_1 article-title: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_70_1 doi: 10.1093/brain/awv054 – ident: e_1_2_8_207_1 doi: 10.1002/mus.20664 – ident: e_1_2_8_108_1 doi: 10.1111/j.1468-1331.2009.02802.x – ident: e_1_2_8_113_1 doi: 10.1007/s00415-013-7123-8 – volume: 8 start-page: 285 year: 2019 ident: e_1_2_8_15_1 article-title: Compliance with international guidelines for chronic inflammatory neuropathies publication-title: Eur J Neurol – ident: e_1_2_8_192_1 doi: 10.1212/01.WNL.0000134676.05850.C0 – ident: e_1_2_8_107_1 doi: 10.1136/jnnp-2014-309042 – ident: e_1_2_8_93_1 doi: 10.1002/mus.20022 – ident: e_1_2_8_89_1 doi: 10.1002/mus.21186 – ident: e_1_2_8_49_1 doi: 10.1136/jnnp-2013-306105 – ident: e_1_2_8_59_1 doi: 10.1002/mus.23821 – ident: e_1_2_8_81_1 doi: 10.1212/NXI.0000000000000149 – ident: e_1_2_8_51_1 doi: 10.1093/brain/119.3.765 – ident: e_1_2_8_78_1 doi: 10.1212/NXI.0000000000000603 – ident: e_1_2_8_7_1 doi: 10.1212/01.wnl.0000260972.07422.ea – ident: e_1_2_8_90_1 doi: 10.1002/mus.880160304 – ident: e_1_2_8_151_1 doi: 10.1136/jnnp-2011-301706 – ident: e_1_2_8_176_1 doi: 10.1111/ene.13218 – ident: e_1_2_8_186_1 doi: 10.1212/WNL.0b013e3181d1a862 – ident: e_1_2_8_197_1 doi: 10.1212/WNL.58.12.1856 – ident: e_1_2_8_18_1 doi: 10.1136/bmj.i2089 – reference: 34152068 - Eur J Neurol. 2021 Nov;28(11):3545-3546 – reference: 35032084 - Eur J Neurol. 2022 Jan 14;: |
| SSID | ssj0002720 |
| Score | 2.7015023 |
| Snippet | Objective
To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Methods
Seventeen disease experts, a... To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient... ObjectiveTo revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).MethodsSeventeen disease experts, a patient... To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).OBJECTIVETo revise the 2010 consensus guideline on... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3556 |
| SubjectTerms | CIDP Corticoids Corticosteroids Criteria Data search Demyelination Diagnosis Diagnostic systems GRADE guideline Humans Immunoglobulins Immunoglobulins, Intravenous - therapeutic use Immunomodulation Inflammation Intravenous administration Maintenance Medical diagnosis Neurology Pain Peripheral Nerves Peripheral neuropathy Plasma Exchange Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - diagnosis Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - therapy Steroids treatment |
| Title | European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fene.14959 https://www.ncbi.nlm.nih.gov/pubmed/34327760 https://www.proquest.com/docview/2582346323 https://www.proquest.com/docview/2557228403 |
| Volume | 28 |
| WOSCitedRecordID | wos000679448800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Free Archive customDbUrl: eissn: 1468-1331 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002720 issn: 1351-5101 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1468-1331 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002720 issn: 1351-5101 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LbtQwFLXaKULd8KYMlMogFmwCGTsPB1YIZgRSGVXQitlFfqKBIamSTqXZ8RF8FN_Bl3Cv40RUgITELo8b25LPda7v45iQRxNuMDyno0RzHiXCxlGhDUwITwtntQNd9zyzh_l8LhaL4miLPO9rYTp-iMHhhprh12tUcKnaX5QcloInaN4X22SHAW7TEdl59W52cjgsxBhi9PutdBIh9AKxECbyDB9f_B39ZmNeNFn9P2d29b9Ge41cCaYmfdFh4zrZstUNcvltCKbfJN97TzztkuQ3tHbUk3Wgp_3pEWDTcw6s4GFzbmlI8KQf10iNBU3QuqKmS9VbtlRWhg5p69iU7nh3KWAYYPfFh_Mp9oMfS0y3pqf1atNIgz7I2jNr4gHJm2e02xZgI5J-qpfQ3rFsP9NZ3Wj74-u397iLN7QJlfG3yMlsevzydRQOdog0x6wqrjJptXHcTLRQznKsa8-kEyqPFRiQE6GMyWKZ8lxIJ4VjiiWSp4LbpEAfzG0yqmBYdwhVDlYkMNqsKuJE2VyBPep0wYVJmUuYGZPH_fyWOrCe4-Ebq7Lf_cDMlH5mxuThIHraUX38SWi_B0kZtL0tWSoYTzLO-Jg8GF6DnmLwRVa2XqNMmjOwBWKQ2evANfSCxb15nsUwWI-hv3dfTudTf3H330XvkV2GiTi-gHKfjM6atb1PLunzs2XbHJDtfCEOgurA3Yc3858kgCJb |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JbtRAEC2FgAgX9sBAgAZx4GLwuL20EReEZpSIiRWJQeRm9YoGBjvyZCLNjY_go_gOvoSq9iIiQELiZtnVi9RV7de1vAZ4OuaGwnM6iDXnQSxsGOTa4ILwJHdWO7R1zzM7y4pCHB_nR1vwqq-FafkhBocbWYbfr8nAySH9i5XjXvCc8H1-AS7GCDTo4oYPB8WwD1OE0R-3knFAmtfxClEez9D0_N_oN4h5HrH6X8702v9N9jpc7aAme93qxg3YstVNuHzYBdNvwffeE8_aJPkNqx3zZB3kaX9xhLrpOQeW-LI5s6xL8GQf10SNhV2wumKmTdVbrJisDBvS1qkr3fLuMtRhVLsvPpzPaBxqLCndmp3Uy00jDfkga8-sSRckb16y9lhAnUj2qV5gf3O5-symdaPtj6_f3tEp3rCmq4y_De-nk_mb_aC72CHQnLKquEql1cZxM9ZCOcuprj2VTqgsVAggx0IZk4Yy4ZmQTgoXqSiWPBHcxjn5YHZhu8Jp3QWmHO5ICNqsysNY2UwhHnU658IkkYsjM4Jn_QKXumM9p8s3lmV_-sGVKf3KjODJIHrSUn38SWiv15Kys_ZVGSUi4nHKIz6Cx8NntFMKvsjK1muSSbIIsUCIMnda7RpGoeLeLEtDnKxXor8PX06KiX-49--ij2Bnf344K2cHxdv7cCWipBxfTLkH26fN2j6AS_rsdLFqHnr7-QkvryMm |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6VFFVceD8CBRbEgYuL4_VjjbggmghEiCJopd6sfaJAsCOnqZQbP4Ifxe_glzCzfogKkJC4Wfbs7Eo7M56dx7cAT0bcUHpOB7HmPIiFDYNcG9wQnuTOaoe67nFmp9lsJk5O8vkOvOh6YRp8iD7gRprh7TUpuF0Z94uWoy04IP8-vwC7MV0iM4Ddw_eT42lviSnH6A9cySgg2WuRhaiSpx98_n_0m5N53mf1P53Jlf9b7lW43Dqb7GUjHddgx5bXYe9dm06_Ad-7WDxryuS3rHLMw3VQrP3ZHKXTow4s8WV9Zllb4sk-bggcC1mwqmSmKdZbrJksDesL14mVbpB3GUoxCt4Xn9BnNA8NllRwzVbVcltLQ1HIymNr0hXJ2-esORgQE8k-VQvkdyTXn9mkqrX98fXbBzrHG1a3vfE34XgyPnr1Omivdgg0p7oqrlJptXHcjLRQznLqbE-lEyoLFbqQI6GMSUOZ8ExIJ4WLVBRLnghu45yiMLdgUOKy7gBTDm0Sum1W5WGsbKbQI3U658IkkYsjM4Sn3QYXusU9p-s3lkV3_sGdKfzODOFxT7pqwD7-RLTfSUnR6vu6iBIR8TjlER_Co_4zaiqlX2Rpqw3RJFmE3kCINLcb6epnofbeLEtDXKwXor9PX4xnY_9w999JH8Le_HBSTN_M3t6DSxFV5fhuyn0YnNYbex8u6rPTxbp-0CrQTxXRI88 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=European+Academy+of+Neurology%2FPeripheral+Nerve+Society+guideline+on+diagnosis+and+treatment+of+chronic+inflammatory+demyelinating+polyradiculoneuropathy%3A+Report+of+a+joint+Task+Force%E2%80%94Second+revision&rft.jtitle=European+journal+of+neurology&rft.au=Van+den+Bergh%2C+Peter+Y.+K.&rft.au=Doorn%2C+Pieter+A.&rft.au=Hadden%2C+Robert+D.+M.&rft.au=Avau%2C+Bert&rft.date=2021-11-01&rft.issn=1351-5101&rft.eissn=1468-1331&rft.volume=28&rft.issue=11&rft.spage=3556&rft.epage=3583&rft_id=info:doi/10.1111%2Fene.14959&rft.externalDBID=10.1111%252Fene.14959&rft.externalDocID=ENE14959 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-5101&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-5101&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-5101&client=summon |